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 Advancement of stem cell therapy is dependent upon the practicality, safety, and efficacy 
of the cells being evaluated for clinical application.  Over the past decade, the need for banked 
stem cells which are readily available for use at the time of a patient’s diagnosis has become 
apparent.  The overall goal of this dissertation research was to compare induced pluripotent stem 
cells (iPSCs) to bone marrow-derived mesenchymal stem cells (MSCs), first in terms of their 
ability to be generated from genetically diverse individuals, and then in terms of their 
immunogenic and immunomodulatory properties for potential allogeneic use. 
 It has previously been demonstrated in mice that genetic background affects the 
proliferation and differentiation rates of MSCs.  The purpose of our first study was to determine 
if genetic background affects the efficiency of generating iPSCs from mice.  Results of this study 
confirmed that genetic background does affect both the efficiency of generating iPSCs during the 
early stages of reprogramming as well as the pluripotent stability of the iPSCs during later stages 
of reprogramming.  The results also confirmed the need to understand the immunogenic and 
immunomodulatory properties of these cells for potential allogeneic application given that it may 
not be feasible to generate iPSCs from all individuals or to wait for the time that it takes to 
generate iPSCs and then screen them for safety and efficacy. 
  
 The purpose of our second study, therefore, was to evaluate the in vitro immunogenic and 
immunomodulatory properties of murine iPSCs compared to MSCs using modified mixed 
leukocyte reactions. Our comparisons revealed that iPSCs generated through both lentiviral and 
piggyBac reprogramming methods had similar immunogenic properties as MSCs, and more 
potent immunomodulatory effects than MSCs.  This information is critical when considering the 
use of iPSCs in the place of MSCs for both regenerative medicine and transplant medicine.  
Further studies must be performed, however, in order to determine if iPSCs retain their 
immunogenic and immunomodulatory properties upon differentiation into specific cell or tissue 
types. 
 With this knowledge, we then shifted the focus of our third study to the horse, which is a 
valuable model for the human immune response. The purposes of this study were to 
immunophenotype MSCs from horses of known MHC haplotype and to compare the 
immunogenicity of MSCs with differing immunophenotypes, particularly in regards to MHC 
class II expression, through modified mixed leukocyte reactions.  Results of this study 
demonstrated for the first time the extreme heterogeneity that exists in MHC class II expression 
by equine MSCs and that MHC class II positive equine MSCs are capable of inciting an immune 
response in vitro.  This knowledge is critical for the treatment of our equine patients as well as 
for studies using the horse as an animal model for human diseases.  Future experiments to 
determine if we can modulate this MHC class II expression in culture will be of great interest 
prior to performing in vivo studies to examine the immune response to allogeneic equine MSCs, 
and ultimately to compare allogeneic equine MSCs to iPSCs both in terms of their immunogenic 
and immunomodulatory properties as well as their regenerative ability.  
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CHAPTER 1 
GENERAL INTRODUCTION 
 
Overall Goal of Dissertation Research 
 Advancement of stem cell therapy is dependent upon the practicality, safety, and efficacy 
of the cells being evaluated for clinical application.  The overall goal of this dissertation research 
was to compare induced pluripotent stem cells (iPSCs) to bone marrow-derived mesenchymal 
stem cells (MSCs) first in terms of ability to be generated from genetically diverse individuals, 
and then in terms of immunogenic and immunomodulatory properties.  The remainder of this 
chapter provides relevant background information, the rationale for this overall goal, and the 
specific objectives and hypotheses for the studies presented in chapters 2 through 4.   
 The laboratory mouse was ideal to address the questions of the first two studies presented 
(chapters 2 and 3) due to the variety of readily available inbred strains and the well-established 
reprogramming methods used to generate mouse iPSCs.   With this knowledge, we then shifted 
our focus to the horse for the third study (chapter 4) in order to further immunophenotype equine 
MSCs for future use in immunologic and regenerative studies comparing iPSCs to MSCs.  This 
knowledge on equine MSCs, along with very recent publications on the generation of equine 
iPSCs [1-3], makes the horse an ideal candidate for such studies.  
 The horse is superior to the mouse as a model for many reasons.  The horse allows for 
non-invasive access to large quantities of samples such as blood, bone marrow, serum, and skin 
needed to generate and test iPSCs from intentionally major histocompatibility complex (MHC)-
matched or mismatched animals.  The amount of tissue available allows for thorough studies of 
biological, histological, mechanical, and functional outcome data. The horse is also a valuable 
model for the study of the human immune response because the horse and human genome have 
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high homology, and the horse and human have similar primary immunodeficiencies indicating 
that horses are a good choice to model the human immune response [4-8].  Most importantly, 
horses and humans form outbred species, unlike many laboratory animals.   
 Finally, proof of efficacy and safety in horses is commonly required by regulatory 
agencies prior to the approved use of regenerative therapies in humans because horses more 
closely approximate the situation in and response to treatment of human patients when compared 
to laboratory species [9].  The end of the chapter includes a review of the current status of 
clinical stem cell use in the horse.  This review is important to understand what evidence 
presently exists to justify the use of stem cells in horses and how we as equine surgeons can 
advance the field of regenerative medicine as a whole by performing carefully controlled 
experimental and clinical trials that are then directly translatable to humans. 
 
History of Bone Marrow-Derived Mesenchymal Stem Cell (MSC) Research 
 Adult bone marrow-derived mesenchymal stem cells (MSCs) were first discovered in 
experiments performed by Friedenstein and colleagues in the 1960s and 1970s [10-12].  In these 
experiments, they demonstrated that fibroblastoid cells could be isolated from the bone marrow 
and that these cells were able to adhere to plastic and form colonies [10].  Although Friedenstein 
also demonstrated the osteogenic potential of MSCs, it wasn’t until the late 1990s that Pittenger 
and colleagues demonstrated the in vitro ability of MSCs to differentiate into cells of osteogenic, 
chondrogenic, and adipogenic lineages [13].  This seminal work, which also included 
characterization of cell surface markers on MSCs using flow cytometry, renewed worldwide 
interest in MSCs [11-13].  Despite a large body of research since that time, many unanswered 
questions remain concerning both the safety of MSCs for allogeneic applications and the 
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regenerative ability of MSCs for the treatment of naturally occurring diseases.   Clinical trials 
in both humans and animals using MSCs have shown only modest results, leading many 
researchers to now believe that their positive effects on tissue repair are due to the soluble factors 
they secrete which may promote endogenous cell survival by inducing angiogenesis, decreasing 
the inflammatory and immune responses, and reducing apoptosis [14-19]. 
 
Immunogenic and Immunomodulatory Properties of Bone Marrow-Derived Mesenchymal 
Stem Cells 
 It has been demonstrated that MSCs have low immunogenicity when used autologously 
and that they possess significant immunomodulatory properties [20-25].  Many mechanisms for 
the immunosuppressive effects of MSCs have been described including inhibition of T cell 
proliferation, alteration of dendritic cell maturation, induction of regulatory lymphocytes, and 
apoptosis of CD8 positive T cells [21, 22, 26-28].  Although it was initially believed and 
demonstrated that allogeneic MSCs can be immune privileged due to these immunosuppressive 
properties [29-31], immune rejection of allogeneic MSCs has been reported [32-37].    
 The finding that MSCs are capable of alterations in their MHC class I and II expression 
profiles is likely to blame for these conflicting results.  While adult MSCs generally display the 
phenotype of high MHC class I expression and low or negative MHC class II expression, MSCs 
from mice and humans with high MHC II expression levels have also been described [32, 33, 
38].  Additionally, both MHC class I and class II expression levels on MSCs can be upregulated 
by proinflammatory cytokines such as IFN-ɣ [39, 40].  It is therefore necessary to carefully 
immunophenotype MSCs to be used in immunologic studies as those MSCs expressing high 
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levels of MHC class II are more likely to incite an immune response compared to those that are 
MHC class II negative. 
 In order to determine the in vitro immunogenicity and immunomodulatory capabilities of 
MSCs, researchers have relied on modified one-way mixed leukocyte reactions (MLRs) as 
described and used in this dissertation research.  In MLRs, one population of cells is referred to 
as the responder cell population while another is referred to as the stimulator cell population.  
Responder cells are leukocytes that will divide in response to a stimulus and are typically 
harvested from either peripheral blood or lymphoid organs such as the spleen.  Stimulator cells 
are the cells responsible for responder leukocyte proliferation and can either be leukocytes 
(classic MLR) or another cell type such as stem cells in this case.  Stimulator leukocytes used in 
classic MLRs to determine histocompatibility or used in modified MLRs as controls must be 
irradiated or treated with Mitomycin C to prevent cell division.  This cell division would 
otherwise be indistinguishable from that of the responder cells when using 
3
H-thymidine labeling 
[41, 42]. Even with newer labeling methods such as 5(6)-carboxyfluorescein diacetate N-
succinimidyl ester (CFSE) used in this dissertation research, in which responder leukocytes alone 
are labeled prior to culture, stimulator leukocyte response and division is still undesirable due to 
media exhaustion [42].  In modified MLRs, stem cell division can be inhibited if using 
3
H-
thymidine for labeling but otherwise the cells can be seeded at low density at the establishment 
of cultures and left to divide provided that the amount of media is adequate.  In order to examine 
the immunomodulatory effects of stem cells, classic MLRs are carried out in tissue culture wells 
with responder leukocytes of one haplotype and stimulator leukocytes of a different haplotype 
either alone (as a control) or in the presence of stem cells seeded on the bottom of the wells.   
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 Antigen presentation in MLRs can occur via direct or indirect antigen presentation 
pathways [43-45].  Two direct antigen presentation pathways have been described. The first 
relies on the presentation of stimulator antigens by stimulator antigen presenting cells (APCs) to 
responder T cells.  The second is caused by direct recognition of allogeneic stimulator MHC 
molecules by responder T cells.  The indirect antigen presentation pathway relies on the 
presentation of shed stimulator MHC molecules (generally following cell death) by responder 
APCs [43-45].  For all of these pathways, the expression of MHC class I and II molecules by 
stem cells is critical to the MLR response elicited. 
 
History of Induced Pluripotent Stem Cell (iPSC) Research 
 Induced pluripotent stem cells (iPSCs) were first generated from adult mouse fibroblasts 
by Takahashi and Yamanaka in 2006 using retroviral transfection of Oct3/4, Sox2, Klf4, and c-
Myc factors under embryonic stem cell (ESC) culture conditions [46].  The iPSCs were shown to 
be ESC-like based on their capacity to form embryoid bodies in vitro and to form teratomas in 
SCID mice [46]. Shortly thereafter, it was also demonstrated that mouse iPSCs were able to give 
rise to germ line chimeras [47].  Reports of the generation of iPSCs from adult human fibroblasts 
quickly followed in the literature [48-50] and iPSCs became regarded as the most promising 
candidate for the clinical application of regenerative therapies [51].   
 The immediate and intense focus on iPSCs was due to the fact that they are pluripotent, 
unlike MSCs, and can be autologous or patient-specific, unlike ESCs.  At a time when MSC 
clinical studies began showing either very modest regenerative potential or no beneficial effects 
at all, iPSCs were a new source of hope for the field.  In addition, because iPSCs can be 
generated from somatic cells, they avoid the ethical concerns surrounding the isolation and use 
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of human ESCs [51], making them a more attractive option to the general public.  It did not take 
long, however, for iPSCs to come under attack as concerns were raised over their safety in terms 
of genetic instability and tumorigenic potential [51, 52].    
 Retroviruses and lentiviruses are highly efficient at generating iPSCs but lead to genomic 
integration of the transgenes, some of which are known oncogenes such as Klf4 and c-Myc [51, 
53].  For that reason, many groups have since successfully investigated the use of non-integrating 
reprogramming methods to generate iPSCs including the use of plasmids, proteins, adenoviruses, 
Cre-recombinase excisable lentiviruses, and transposases such as the piggyBac transposase [51, 
53-59].  Similarly, many groups are investigating reprogramming methods that exclude the 
factors Klf4 and c-Myc [2, 51, 53, 60]. Nevertheless, it has become apparent that iPSC lines 
generated from any of these reprogramming methods have the potential for karyotypic and 
genomic aberrations, and therefore must be thoroughly screened for safety prior to clinical use 
[52, 57, 61-64]. 
 Despite the tremendous potential placed on iPSCs for patient-specific use, the practicality 
of such autologous iPSC use has recently been called into question [57, 65].  Under optimal 
conditions, iPSCs take several months to culture expand and evaluate for pluripotency [48, 55, 
57, 66].  The addition of screening for genetic instability adds even more time to this already 
extended process, making autologous iPSC use impractical for many of these diseases that would 
potentially benefit from stem cell therapy.  This led us to two important questions concerning 
iPSCs that would have a significant impact on their future clinical application: (1) Does genetic 
background affect iPSC generation; and (2) What are the immunogenic and immunomodulatory 
properties of iPSCs?  Our hypotheses for iPSCs were based on previous findings for ESCs, 
which are detailed below. 
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Effect of Genetic Background on Stem Cell Derivation 
 It has been previously demonstrated in mice that genetic background affects the ability to 
derive ESCs [67-69].  Some strains such as 129/Sv are noted for the ease in which ESC lines can 
be established, while others such as BALB/c are notoriously difficult to establish ESC lines 
from, requiring alternate culture conditions and a particularly high concentration of Leukemia 
Inhibitory Factor (LIF) to maintain pluripotency [67, 69].  Because of this precedence, our 
hypothesis was that genetic background would also affect the ability to generate iPSCs.  Results 
of this study, presented in chapter 2, confirmed this hypothesis.  The results also confirmed the 
need to understand the immunogenic and immunomodulatory properties of these cells for 
potential allogeneic application given that it may not be feasible to generate iPSCs from all 
individuals.  
 Both genetic background and age of the patient have also been shown to affect 
proliferation and differentiation rates of MSCs [70-72], suggesting that autologous MSC use also 
may not be feasible for some patients.  Given these findings and the fact that the future of stem 
cell therapy is headed toward the use of banked stem cells that have been tested for both efficacy 
and safety [65, 73], we sought to compare the immunogenic and immunomodulatory properties 
of iPSCs and MSCs for potential use in regenerative and transplantation medicine.   
 
Immunogenic and Immunomodulatory Properties of Embryonic Stem Cells (ESCs) 
 At the time of this dissertation research, no studies had been published examining the 
immunogenic properties of iPSCs. It has since been demonstrated, however, that undifferentiated 
iPSCs, like ESCs, express low or absent levels of MHC class I and are negative for MHC class II 
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expression [74].  Interestingly, it has also been shown that MHC class II expression on iPSCs is 
not upregulated by differentiation or by stimulation with IFN-ɣ [74]. The extent to which MHC 
class I expression can change upon iPSC differentiation or stimulation with proinflammatory 
cytokines is unknown.  Several studies have shown that MHC class I expression increases upon 
iPSC differentiation and with IFN-ɣ stimulation, but often only to a level still much less than that 
of somatic cells [74-76].  The consequence of such a change in MHC class I expression is 
complex as a high expression level of MHC class I could lead to T cell activation, while a 
continued lack of MHC class I expression could potentially lead to iPSCs being targeted by 
natural killer (NK) cells in vivo [77].  Conflicting results have been reported for ESCs on this 
subject, with some groups reporting ESCs as susceptible to NK cell lysis, and others reporting 
that ESCs are neither susceptible to NK cell lysis nor capable of eliciting T cell responses [77, 
78].   
 Since the start of this dissertation research, conflicting results have also been reported on 
the immunogenicity of iPSCs. While the first report on the immunogenicity of iPSCs revealed 
that undifferentiated autologous  mouse iPSCs were immune rejected in a teratoma model study 
[79], two other reports since then have shown that both undifferentiated and differentiated 
syngeneic mouse iPSCs are non-immunogenic in vitro and in vivo [75, 76].  To date, no studies 
have examined the immunomodulatory properties of iPSCs even though it is known that ESCs 
are capable of immunosuppression through multiple mechanisms including expression of 
arginase I, prevention of dendritic cell maturation, and upregulation of regulatory T cells [80-83].  
When considering the use of iPSCs as an alternative for MSC therapy, this information is 
critical.  The purpose of the study presented in chapter 3, therefore, was to evaluate the in vitro 
immunogenic and immunomodulatory properties of iPSCs compared to MSCs using modified 
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mixed leukocyte reactions.  Our hypothesis, based on prior ESC knowledge, was that 
undifferentiated iPSCs would have similar immunogenic and immunomodulatory properties as 
MSCs.  Results of this study confirmed this hypothesis and have led us to design future studies 
(outside the scope of this dissertation) using the horse as model to then compare the regenerative 
ability of iPSCs and MSCs in vivo. 
 
Development of Equine Induced Pluripotent Stem Cells 
 An exciting development to occur during the course of this dissertation research was the 
generation of equine iPSCs, first by Nagy et al. [1] and then by Khodadadi et al. [2] and Breton 
et al [3].  Nagy et al. reprogrammed equine fetal fibroblasts to iPSCs using the doxycycline-
inducible piggyBac transposon reprogramming system.  Both Khodadadi et al. and Breton et al. 
reprogrammed adult fibroblasts to iPSCs using a constitutive retrovirus or Moloney Murine 
Leukemia Virus, respectively [2, 3].   With the aid of these publications, and our collaborators 
from the Nagy laboratory, we are currently working towards generating iPSC from horses of 
known MHC haplotype to be used for future experiments and compared to the MSCs that we 
have already isolated from these horses as described in chapter 4 and discussed below. 
 
Current Status of Clinical Stem Cell Use in The Horse (Modified from: Schnabel LV, Fortier, 
LA, McIlwraith CW, Nobert KM.  Therapeutic use of stem cells in horses: Which type, how, and 
when?  Vet J.  In Press.) 
 The use of stem cells in veterinary medicine continues to increase at a pace that is more 
rapid than available scientific and clinical evidence [84-87].  Despite the widespread use of stem 
cells for the treatment of equine musculoskeletal disorders, there are very few reports of long-
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term clinical data.  Many experimental and clinical studies are lacking the proper control groups 
and are complicated by multimodal therapeutic approaches. In addition, there are impending 
changes in regulatory laws by the FDA, which eventually may limit the use of some or all types 
of equine stem cells [88, 89].  When considering our equine patients and also the fact that the 
horse is a valuable model for the human response to stem cell treatment, we must take caution in 
how future equine studies are designed and executed and how stem cells are used on a daily basis 
so as not to bias any findings. 
 The two most commonly used stem cells in equine veterinary medicine are adult bone 
marrow-derived and adipose tissue-derived mesenchymal stem cells (MSCs) [85, 86, 90].  Cells 
from either of these sources can be used after a culture period or after a brief centrifugation step 
for point-of-care treatment.   Bone marrow aspirate is typically harvested from the sternum 
(marrow spaces 3 to 5) or ilium using a Jamshidi needle [91, 92].  The bone marrow aspirate can 
be cultured for approximately 2-3 weeks to obtain bone marrow-derived mesenchymal stem cells 
(BM-MSCs) or immediately centrifuged patient-side to produce bone marrow concentrate 
(BMC).  BMC concentrates both stem cells and platelets compared to raw bone marrow aspirate, 
but yields a much lower number of stem cells compared to culture-expanded BM-MSCs [93].  
Both BM-MSC isolation/culture services and BMC centrifugation systems are available 
commercially and are frequently used by equine practitioners [90, 93, 94].   
Adipose tissue is generally harvested from the tail head region and then collagenase 
digested and either cultured for several weeks to obtain adipose tissue-derived MSCs (AT-
MSCs) or processed commercially to isolate adipose-derived stem vascular fraction (AD-SVF) 
cells within 4-24 hours [90].  Although equine AT-MSCs have been well described in the 
literature [95-100], AD-SVF cells have been favored over AT-MSCs in clinical use most likely 
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due to their highly publicized commercial availability and short turnaround time from adipose 
tissue harvest to clinical application [90].  It is important to note, however, that because of the 
lack of a culture step, only a fraction (20 to 40%) of the AD-SVF cells are stem cells [98]. As 
detailed below, there is evidence to support the use of both cultured and processed adult MSCs 
for the treatment of equine musculoskeletal disorders including tendonitis and osteoarthritis. 
 Umbilical cord tissue-derived and placentally-derived MSCs have been assessed for 
safety in the literature primarily because of the fact that they are generally used in an allogeneic 
fashion [101, 102], but have not yet been evaluated for efficacy in the treatment of any equine 
disorder.  Despite this fact, umbilical cord-derived MSCs are being used clinically and so are 
mentioned here.  Only those stem cells for which peer-reviewed publications containing pre-
clinical and/or clinical data exist, however, will be discussed further.  
Tendonitis: The use of cultured bone marrow-derived MSCs (BM-MSCs) for the treatment of 
equine tendonitis is supported in the literature both by experimental and clinical studies [103-
107].  Peer-reviewed publications with clinical data only currently exist for BM-MSCs and not 
for other types of stem cells.  Smith et al. (2003) first described the culture process and use of 
BM-MSCs for the treatment of naturally occurring superficial digital flexor tendonitis in a single 
case report of a polo pony [108].  In the first case controlled study on the use of BM-MSCs for 
the treatment of naturally occurring superficial digital flexor tendonitis by Pacini et al. (2007), 11 
BM-MSC treated horses were compared to 15 control horses treated by traditional methods with 
both groups using the same rehabilitation protocol [104].  In this study, 9/11 (82%) of the BM-
MSC treated horses returned to racing in 9-12 months and were still racing without re-injury at 2 
years post-treatment compared to the control group in which all of the 15 horses had experienced 
a re-injury event within 1 year (median re-injury time of 7 months) [104].   
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 In a later large clinical case series by Godwin et al. (2012) in which BM-MSC treated 
horses were compared to historical controls from the literature [109, 110], a significant reduction 
in re-injury rate was found for National Hunt horses treated with BM-MSCs compared to 
National Hunt horses treated with other  therapies as previously reported by Dyson (2004) 
(25.7% compared to 56%, respectively) and O’Meara et al. (2010) ( 25.7% compared to 53%, 
respectively).  Interestingly, no differences in the percentage of National Hunt horses treated 
with BM-MSCs compared to historical controls as reported by O’Meara et al. was found in terms 
of return to racing and completing 3 and 5 races.  Only 8 Thoroughbred flat racehorses treated 
with BM-MSCs were compared to 3 Thoroughbred flat racehorses treated with medical therapies 
by Dyson et al. (2004).  The small sample sizes in each study make translation of these findings 
to Thoroughbred flat racehorses difficult. 
For the treatment of discrete core lesions, stem cells should be injected directly into the 
lesion under ultrasound guidance using aseptic technique [103-105, 107].  Use of a 20 or 23 
gauge needle is recommended for direct injection based on work from our laboratory in which 
the use of needles smaller than 23 gauge resulted in significantly decreased BM-MSC viability 
compared to larger gauge needles. This effect is presumed to be due to increased mechanical 
shearing of the cells with decreased needle size [111].  For diffuse tendon or suspensory ligament 
lesions, or for multiple lesions within the same tendon/ligament or limb, administration of stem 
cells via intravenous regional limb perfusion should be considered based on a recent study by 
Sole et al. [112].   Either intravenous catheters or butterfly needles size 23 gauge or larger are 
recommended for this technique for ease of slow administration and to avoid decreased cell 
viability as discussed above.  As reported by Sole et al. (2012), intra-arterial regional limb-
perfusion should be avoided at this time due to the potential for arterial thrombosis [112].   
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Studies to determine the optimal number of stem cells for the treatment of 
tendon/ligament lesions in the horse have yet to be performed.  A range of BM-MSC numbers 
has been described in the literature for therapeutic application with the most common being 
10x10
6 
BM-MSCs per tendon lesion [103-105, 107].  Horses with unfavorable outcomes in both 
the Pacini et al. (2007) and Godwin et al. (2012) studies were injected with fewer BM-MSCs 
compared to horses with favorable outcomes, however these results are limited in sample size.  It 
is likely that a range exists within which stem cell numbers are most effective.  Dose-dependent 
response studies are needed in the horse to determine this range. 
While all of the peer-reviewed publications on the use of BM-MSCs for the treatment of 
tendonitis have relied on a single injection, it is common in clinical practice to perform multiple 
injections depending on healing of the injured tendon.  Our clinical practice is to perform a 
recheck examination of the horse at 30 days post initial injection and to repeat BM-MSC 
treatment if there is a less than fifty percent improvement in both the degree of lameness and 
ultrasonographic evaluation findings.  A rehabilitation protocol is also essential for success and 
must be tailored to each individual horse according to physical examination and lameness 
evaluation findings in conjunction with ultrasonographic findings.  For that reason, it might be 
prudent to provide owners with instruction only until the time of the horse’s next recheck 
examination with specific but gradual increase in exercise as opposed to box stall rest, as has 
been described in the literature [107].   
Further studies need to be performed to determine if the use of BM-MSCs is more or less 
effective than the use of platelet-rich plasma (PRP) for the treatment of tendonitis or if their 
effects are additive if used simultaneously.  It is common in clinical practice to administer PRP 
at the time of diagnosis and bone marrow aspiration, with a second injection of BM-MSCs and 
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PRP when the cultured BM-MSCs are ready.  Stem cells and PRP should not be mixed together 
in the same syringe as the PRP may clot prohibiting injection.  To circumvent this possibility, 
they can be injected sequentially using the same needle, but not mixed together prior to injection. 
Our laboratory and others are currently investigating the chemotactic properties of biologics such 
as PRP for the recruitment of endogenous MSCs from normal tissue surrounding the injury site 
[113]. 
Joint disease: The efficacy of stem cells for the treatment of equine osteoarthritis (OA) and 
cartilage injuries has been evaluated in the form of experimental and clinical studies and with 
more favorable results for bone marrow-derived cells than adipose-derived cells [93, 114-116].  
In the only study published on the use of intra-articularly administered stem cells for the 
treatment of OA in the horse, Frisbie et al. (2009) created early OA using a carpal osteochondral 
fragment model [115, 117]. Injured joints were treated once with cultured BM-MSCs, AD-SVF 
cells, or saline.  At 70 days post-treatment, no differences were found in cartilage biochemistry 
or histology between the groups.  Joints injected with BM-MSCs had significantly less synovial 
effusion and lower concentrations of the pro-inflammatory modulator prostaglandin E2 (PGE2) 
in comparison to joints injected with either AD-SVF cells or saline [115].  Treatment with AD-
SVF cells incited an inflammatory response demonstrated by increased concentrations of tumor 
necrosis factor alpha (TNF-α) [115].  A large clinical trial is needed to determine the effects of 
intra-articular administration of BM-MSCs on the progression of naturally occurring OA in 
horses non-responsive to routine treatments [86, 118] .  The results of such a trial would be 
useful for further determining if and how stem cells should be used for the treatment of equine 
OA.  It is possible that MSCs will have more of an effect on horses with advanced OA than that 
which has been observed in experimental OA models.  It is also possible that the MSCs may 
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need to be differentiated prior to administration to be maximally effective for the treatment of 
OA [86, 118]. 
 The efficacy of both cultured BM-MSCs and BMC has been evaluated for the treatment 
of experimentally induced full-thickness cartilage defects created on the lateral trochlear ridge of 
the femur in horses [93, 116]  In the Wilke et al. (2007) study, BM-MSCs in fibrin grafted into 
full thickness cartilage defects resulted in significantly improved arthroscopic scores and biopsy 
assessments at 30 days compared to control defects treated with fibrin alone.  At 8 months, 
however, no differences in BM-MSC treated and control defects were found [116].   It is unclear 
whether the results of these long-term assessments could have been affected by the trauma of the 
30-day biopsy or if the effects of the BM-MSCs were truly short-lived.  Using a similar study 
design, but without a biopsy, Fortier et al. demonstrated the effectiveness of BMC for repair of 
full-thickness cartilage defects [93].  Both short-term (3 month) and long-term (8 month) 
assessments revealed a significant improvement in the macroscopic and histologic scoring for 
BMC grafted and microfracture treated defects compared to control microfracture alone treated 
defects.  At 8 months, BMC grafted defects also had significantly improved magnetic resonance 
imaging measurements compared to control treated defects [93].    
 McIlwraith et al. (2011) also recently evaluated the efficacy of BM-MSCs administered 
intra-articularly for the treatment of microfracture treated full-thickness medial femoral condyle 
cartilage defects [119].  Horses either received BM-MSCs with hyaluronan or hyaluronan alone 
1 month after creation of the defects.  After a year-long period of exercise, horses were 
euthanized.  Horses treated with BM-MSCs had a significant increase in repair tissue firmness 
and concentration of aggrecan compared to control.  No other significant differences were found 
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between treatment and control groups on magnetic resonance imaging and gross, histologic, and 
biochemical examinations [119].   
 In a clinical follow-up of thirty-three horses that received intra-articular BM-MSCs 
following arthroscopic surgery for the treatment of stifle injuries including medial femoral 
condyle cysts and meniscal damage, Ferris et al. reported a low morbidity rate equivalent to that 
of surgery alone or as reported for treatment with common chondroprotective agents [114].  For 
this case series, the authors also reported improved results for horses with meniscal injuries 
being able to return to work compared to previous reports [114]. 
 For the treatment of osteoarthritis (OA), BM-MSCs can be injected intra-articularly either 
alone or in conjunction with products routinely used to treat OA such as hyaluronan.  Current 
recommendation is to inject stem cells (20x10
6
) in HA [22mg of Hyvisc (hyaluronate sodium, 
3x10
6
 Da, Anika Therapeutics, Woburn, MA)] in an OA-affected joint on an as needed basis as 
would be performed if using corticosteroids.  The frequency of injection would therefore vary 
depending on the individual horse and response to treatment.  Administration of a non-steroidal 
anti-inflammatory agent (NSAID) prior to injection of BM-MSCs is recommended to reduce the 
risk of joint flare [114].  While the use of NSAIDs is prudent, the reported occurrence of joint 
flare following intra-articular of BM-MSCs is low (9%) and equivalent or less than that reported 
for HA products alone [114].  If a joint flare where to occur, treatment with NSAIDs alone is 
recommended unless there is concurrent evidence of injection requiring joint lavage [114]. 
 For intraoperative treatment of cartilage defects, BM-MSCs or BMC can be grafted into a 
lesion under arthroscopic guidance [93, 116].  This requires the use of gas arthroscopy at the 
time of grafting.  In most cases, a dual syringe injection system is used in which the cellular 
component is in one syringe and bovine thrombin is in the other syringe; when injected 
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simultaneously, they mix and form a clot that is molded to the contour of the lesion.  
Alternatively, autologous or commercial fibrin can be used to retain the cells.  There are other 
cartilage grafting procedures, such as those using allogeneic chondrocytes in fibrin with insulin-
like growth factor-I (IGF-I) that appear at least equally as efficacious [120, 121], but no direct 
comparative studies between the cartilage repair grafting procedures have been performed.  In 
addition to the grafting techniques described, there is experimental evidence to support the use of 
BM-MSCs injected intra-articularly for the treatment of cartilage defects [119].  This application 
is most commonly used when a diagnosis of cartilage injury is made at the time of arthroscopy 
and no graft material is anticipated as needed or prepared for intra-operative application.  
 As discussed for the treatment of tendonitis, it is unclear at this time if the simultaneous 
use of biologics such as PRP would be of added benefit.  It is also unclear what the optimal 
number of MSCs for the treatment of OA and cartilage defects is as no dose response studies 
have been performed to date.  While published studies most commonly use a range of 10x10
6
 to 
20x10
6 
BM-MSCs per joint/cartilage defect, cell numbers can be larger, particularly for the 
grafting of large defects.   
 Following intra-articular injection of stem cells for the treatment of OA in the absence of 
surgery, horses are returned to exercise after 24 hours similar to more routine treatment with 
corticosteroids and/or chondroprotective agents.  Following a surgical stem cell grafting 
procedure, a rehabilitation protocol is established and is largely dependent on the size, location, 
and nature of the cartilage defect. Young horses treated for osteochondritis dissecans (OCD) 
lesions are generally confined to a box stall for 2 weeks post-operatively, following which time 
gradually increasing amounts of hand walking are initiated.  At 3 months post-operatively, a 
veterinary examination is performed and radiographs of the affected joint are taken and 
 18 
 
evaluated for healing prior to small paddock turnout for an additional month and then full turnout 
for another 2 months. Veterinary examination and radiographs at 6 months postoperatively are 
then used to determine if the horse can start training.  Adult horses treated for traumatic lesions 
without surgery, may start handwalking as early as 7 days post-injection and are evaluated at 1 
month post-injection to further define an exercise protocol dependent on the particular horse, the 
type and magnitude of articular damage, and the horse’s discipline. 
Laminitis: There is a great deal of hope in the equine community that stem cells may be 
effective in the treatment of laminitis and many practitioners are currently administering stem 
cells from different sources to laminitic horses.  It is important to acknowledge that no studies 
have been performed to evaluate the safety or efficacy of stem cells for the treatment of this 
devastating condition.  While a recent study by Carter et al. (2011) demonstrated that laminitic 
horses have a loss of p63-positive epidermal stem cells compared to control non-laminitic horses, 
it is unknown whether administration of MSCs could aid in the repopulation of epidermal stem 
cells.  It is also unknown if the administration of epidermal stem cells themselves harvested from 
other regions of the horse such as the skin could potentially be effective for the treatment of 
laminitis [122]. 
 Intravenous regional limb perfusion of stem cells is currently being performed clinically 
for the treatment of laminitis.  Owners will seek stem cell therapy as a cure for their horse 
because they know the devastating consequences of laminitis; and while it might be helpful, the 
underlying cause of the disease should be aggressively pursued with diagnostics in conjunction 
with medical management and nutritional therapies.  Ideally, laminitic horses are treated in the 
acute phase in an attempt to decrease the inflammatory response, but this approach would require 
the use of banked-self stem cells or application of allogeneic cells.  For the treatment of 
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laminitis, most horses are treated with stem cells twice, once as early as possible during an acute 
episode and again at 14 days after the first injection.  As previously mentioned, there is currently 
no published data to evaluate the effectiveness of stem cells for laminitis and therefore 
administration techniques, cell types, and cell numbers also have not been evaluated.   
Considerations and cautions for future use of stem cells in the horse: Early administration of 
stem cells is presumed to be advantageous rather than attempt treatment when fibrous scar tissue 
is formed. This paradigm can be accomplished with a point-of-care heterogeneous cell product 
such as BMC, but it often cannot be realized for culture-expanded MSCs unless allogeneic cells 
are used.  Although there is evidence in the literature that MSCs have anti-inflammatory and 
immunomodulatory properties [15, 16, 20, 21, 123-125], it remains unclear if equine MSCs 
incite an immune response in vivo if used allogeneically, especially if administered repeatedly.   
 Preliminary studies by Carrade et al. examined the use of umbilical cord- and placentally-
derived MSCs suggested that such cells do not incite a cellular immune response, even after 
repeated injections [101, 102].  It is important to recognize that MSCs from neonatal sources are 
likely more immune-privileged than those derived from adult sources, and that the horses used in 
these studies were not major histocompatibility class (MHC) haplotyped.  This means that 
although the cells evaluated were not “self”, they might not have been allogeneic in the true 
sense of being of a different MHC haplotype, which would affect their immunogenicity.  In 
addition, it is critical to understand that not all MSCs from the same source are identical and that 
MHC class II expression can vary dramatically depending on the horse and on how many times 
the cells have been passaged.   Our work, as presented in chapter 4 of this dissertation, using 
MHC haplotyped horses revealed that passage 2 BM-MSCs are highly heterogeneous in MHC 
class II expression (range 0 - 98% positive), and that increasing MHC II expression is directly 
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related to increasing responder T cell proliferation in vitro.  Interestingly, BM-MSCs from some 
horses can be negative for MHC class II expression from passage 2 onwards, but the majority of 
horses are positive for MHC class II expression until passage 4 or even later passages.  These 
findings are especially important when considering that most adult source MSCs such as BM-
MSCs are used clinically at very low passage number to maintain stemness. Identification of a 
universal stem cell donor whose low passage BM-MSCs are MHC class II negative would be of 
clinical value.   The fact that BM-MSCs from most horses are MHC class II positive for multiple 
passages and that the amount of MHC class II expression is directly correlated to immune 
response in vitro emphasizes the fact that extreme caution must be exercised in the application of 
allogeneic stem cells from both a safety and regulatory standpoint. 
 The therapeutic application of stem cells in equine veterinary medicine holds great 
promise, but there are also a lot of unanswered questions at this time.  Research efforts must be 
directed towards determining the optimal number of stem cells for each specific clinical 
application as well as the route of administration, dosing formulation, and dosing schedule.  
Particular points of interest are the safety of allogeneic stem cells and the interactions of stem 
cells with biological products, including the ability of biologics to potentially attract stem cells to 
the site of injury.  The idea of a universal BM-MSC donor that would provide the ability to use 
stem cells immediately during the acute phase of the injury or at the time of diagnosis is an 
exciting one for the field of regenerative medicine. 
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Abstract 
 
 The influence of genetic background on the ability to generate induced pluripotent stem 
cells (iPSCs) has the potential to impact future applications, but has yet to be examined in detail. 
The purpose of this study was to determine if genetic background affects the efficiency of 
generating iPSCs during early reprogramming as well as the pluripotent stability of the iPSCs 
during later stages of reprogramming.  Mouse embryonic fibroblasts (MEFs) were isolated from 
six strains of mice (NON/LtJ; C57BL/6J; DBA/2J; BALB/cJ; 129S1/SvlmJ; CAST/EiJ) that 
were selected based on genetic diversity and differences in ability to produce embryonic stem 
cell (ESC) lines. MEFs were reprogrammed via doxycycline-inducible lentiviral transduction of 
murine Oct4, Klf4, Sox2, and c-Myc.  Differences in efficiency to generate iPSCs were assessed 
on primary transformation plates by comparing the total number of colonies, the percentage of 
colonies positive for alkaline phosphatase staining and the percentage of cells positive for 
SSEA1.  iPSC colonies were expanded to establish doxycycline-independent cell lines whose 
pluripotency was then evaluated via ability to form teratomas in NOD.CB17-Prkdc
scid
/J  mice.  
Proliferation of non-transduced parent MEFs from each strain was also examined over ten days 
under conditions that simulated reprogramming.   NON/LtJ and CAST/EiJ strains were more 
efficient than other strains in generating iPSCs for all parameters measured on primary 
transformation plates and parent MEFs from these strains were more proliferative than those 
from other strains.  Doxycycline-independent iPSC lines were established using standard 
conditions for all strains except BALB/cJ, which required a higher concentration (5x) of 
Leukemia Inhibitory Factor (LIF).  iPSCs from all strains were capable of producing teratomas 
in NOD.CB17-Prkdc
scid
/J mice.  The results of this study suggest that genetic background does 
affect iPSC generation and pluripotent stability.  In addition, our results demonstrate that strain 
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differences in efficiency to generate iPSCs during the early stages of reprogramming are 
correlated with those observed in proliferation of parent MEFs.  These findings have important 
implications both for future iPSC applications as well as for future investigation into determining 
the genes responsible for reprogramming efficiency and stability.  
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Introduction 
 The iPSC field continues to make rapid advances in terms of optimizing reprogramming 
methods to circumvent clinical safety issues and characterization of the genetic and epigenetic 
composition of established iPSC lines [1-4].  The influence of genetic background on the ability 
to generate iPSCs, as well as the stability and quality of derived iPSCs for downstream 
applications, also has the potential to impact the future applications.  However, the role of 
genetic background has yet to be examined in significant detail.  The effect of genetic 
background on pluripotency has precedence in mice; it is well documented that there are 
dramatic strain differences in ability to produce embryonic stem cell (ESC) lines [5-8].  
 Many of the mouse iPSC studies to date have used mouse embryonic fibroblasts (MEFs) 
from transgenic mice of an undefined or hybrid background [9], or have used MEFs or tail tip 
fibroblasts (TTFs) derived from animals originally produced from hybrid ESCs [9-16]. Few 
studies have used MEFs or TTFs from a pure inbred strain [17-19].  To our knowledge, only one 
study to date has directly compared the ability of two different inbred strains to generate iPSCs 
[17].  In this study, Hanna et al. found that MEFs from NOD/ShiLtJ mice, a strain previously 
considered nonpermissive for ESC derivation, were capable of generating iPSCs, but that these 
iPSCs were dependent on exogenous transgene expression unlike the iPSCs derived from control 
129Sv/Jae MEFs [17].  The authors determined that the NOD/ShiLtJ iPSCs were dependent upon 
ectopic expression of either KLF4 or c-MYC using constitutive lentiviruses, and that the cells 
were able to overcome this factor dependence when cultured in media supplemented with any of 
the following proteins or small molecules: WNT3a, which promotes iPSC derivation in the 
absence of c-MYC [20]; CHIR99021, a GSK3b inhibitor; or Kenpaullone, a GSK3b and 
CDK1/cyclin B inhibitor which has been shown to replace KLF4 during iPSC reprogramming 
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[17,21]. As the authors concluded, these results suggest that genetic background can affect the 
pluripotent stability of iPSCs and that reprogramming and culture conditions may have to be 
modified for certain strains [17]. 
 The purpose of this study was to determine if genetic background affects the efficiency of 
generating iPSCs during early reprogramming as well as the pluripotent stability of the iPSCs 
during later stages of reprogramming.  We chose six different inbred strains of mice to examine 
based on their genetic diversity [22-24] and on their differences in ability to produce ESC lines 
[5-8]. These six strains included five classical laboratory strains (NON/LtJ, C57BL/6J, DBA/2J, 
BALB/cJ, and 129S1/SvlmJ) and one wild-derived inbred strain (CAST/EiJ) (Figure 2.1).  
Because 129-derived substrains such as 129S1/SvlmJ support facile ESC line derivation while 
both C57BL/6J and BALB/cJ mice do not [5-8], we reasoned that these strains would be useful 
for assessing potential differences in reprogramming efficiency.  In addition, three of the strains 
(C57BL/6J, 129S1/SvlmJ, and CAST/EiJ) are progenitors of the Collaborative Cross that is 
proving effective for analyzing complex genetic phenotypes [25,26].  Knowledge on the 
potential differences between these strains in their ability to generate iPSCs and their pluripotent 
stability might therefore be amenable to genetic analysis.   
 In this study, we show that iPSC lines can be generated from all six of the strains 
examined using a lentiviral reprogramming system [27-29] and that these cell lines are capable 
of forming teratomas in NOD.CB17-Prkdc
scid
/J mice.  We demonstrate, however, that there are 
strain differences in efficiency of iPSC induction, growth, and maintenance requirements, and 
that these strain differences correlate with proliferative ability of the parental MEFs. 
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Figure 2.1.  Mouse family tree.  The seven mouse groups as described as by Petkov et al. [22] 
with the strains examined in this study circled in red.  Group 1, Bagg albino derivatives; Group 
2, Swiss mice; Group 3, Japanese and New Zealand inbred strains; Group 4, C57/58 strains; 
Group 5, Castle’s mice; Group 6, C.C. Little’s DBA and related strains; Group 7, wild-derived 
strains.   (Modified from Petkov et al. and reprinted with permission [22].  The length and angle 
of the branches were optimized for printing and do not reflect the actual evolutionary distances 
between strains.) 
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Materials and Methods 
Mice: Male and female mice from all six strains examined (NON/LtJ; C57BL/6J; DBA/2J; 
BALB/cJ; 129S1/SvlmJ; CAST/EiJ ) were purchased from The Jackson Laboratory (Bar Harbor, 
ME).  For each strain, breeder trios were established for timed matings such that embryonic day 
13.5 embryos could be collected and processed to generate MEFs. NOD.CB17-Prkdc
scid
/J mice, 
used for teratoma formation assays, were also purchased from The Jackson Laboratory (Bar 
Harbor, ME).  The use of mice in this study was approved by the Institutional Animal Care and 
Use Committee of Cornell University. 
MEF culture: Embryonic day 13.5 embryos were isolated from the uteri of pregnant mice, 
lavaged with phosphate buffered saline (PBS), and eviscerated.  Each embryo was then gently 
homogenized in MEF media (high glucose Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 10% Fetal Bovine Serum (FBS), penicillin (100 units/mL), and streptomycin 
(100μg/mL)) and the resultant cell suspension was transferred to a 100mm tissue culture plate 
and incubated at 5%CO2, 90% humidity, and 37°C. The plates were washed with PBS and the 
media changed daily until the MEFs were confluent, at which time they were trypsinized, 
resuspended in freeze media (DMEM with 10% FBS and 10% DMSO), and cryopreserved until 
further use.  All experiments were performed using MEFs derived from two different embryos 
for each strain. 
Lentiviral constructs: Lentiviral vectors for doxycycline-inducible transgene expression were 
constructed as previously described [27-29] using a FUW-based plasmid with a tetracycline 
operator (TetO) and a constitutive CMV promoter.  Briefly, the viral packaging plasmids 
psPAX2 and pMD2.G (Addgene 12260 and 12259, Cambridge, MA) as well as the plasmids 
encoding the reverse tetracycline transactivator (M2rtTA; Addgene 20342, Cambridge MA) and 
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the mouse factors Oct4, Sox2, Klf4 and c-Myc (Addgene 20323, 20326, 20322 and 20324 
respectively, Cambridge, MA) were purified from bacterial cultures. The vectors were then 
prepared by co-transfecting the viral packaging plasmids with plasmids encoding the reverse 
tetracycline transactivator and the reprogramming factors into 293T cells using the FuGENE®6 
Transfection Reagent (Roche Applied Science, Indianapolis, IN). Viral supernatants were 
collected at 48 and 72 hours, concentrated using an Amicon Ultra-15 Centrifugal Filter Unit with 
an Ultracel-30 membrane (Millipore, Billerica, MA), filtered through a 0.45um filter, and stored 
in liquid nitrogen until used. 
Reprogramming of MEFs and iPSC culture: Passage 2 (P2) MEFs from each strain were 
seeded onto gelatin-coated tissue culture plates at a density of 6.75x10
3 
cells/cm
2
 in MEF media 
and allowed to adhere for 24 hours [27].  The culture media was then replaced with fresh MEF 
media supplemented with the viral supernatant described above. Following 24 hours of 
incubation with the viral supernatant, the culture media was changed to ESC media 
(KnockOut
TM
 DMEM (Gibco, Grand Island, NY) supplemented with 15% KnockOut
TM
 Serum 
Replacement (Gibco, Grand Island, NY), recombinant LIF, MEM non-essential amino acids 
solution (100µm), 2mM GlutaMAX
TM 
(Gibco, Grand Island, NY), 0.1 mM 2-Mercaptoethanol, 
penicillin (100 units/mL), streptomycin (100μg/mL), and doxycycline (2µg/mL; Sigma, St. 
Louis, MO)).  Cells destined for flow cytometric analysis and for expansion were kept on 
original 6-well plates while cells destined for AP staining and colony counting were trypsinized 
and passaged onto gelatin-coated 60mm tissue culture plates seeded with feeder cells (Cs 
irradiated C57BL/6J x 129S1/SvImJ1 MEFs) prior to the start of reprogramming with 
doxycycline.  For all plates, ESC media was refreshed daily during reprogramming.     
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AP staining and colony counting: AP staining was performed directly on the 60mm plates using 
the Vector Red Alkaline Phosphatase Substrate Kit (Vector Laboratories, Burlingame, CA) 
according to the manufacturer’s directions.  Both the number of AP stained colonies and the total 
number of colonies on the plates was quantified using bright field microscopy at 100x 
magnification. Colonies were identified based on the following morphological criteria: well 
defined-border; three-dimensionality; and tightly packed cells.  A grid system was used on the 
plates to facilitate colony counting.  Each plate was counted twice and the mean number of AP 
stained colonies and the mean total number of colonies was determined.  The percentage of AP 
stained colonies was determined by dividing the mean number of AP stained colonies by the 
mean total number of colonies and then multiplying by one hundred. 
Flow cytometric analysis: Cells from the 6-well primary transformation plates were trypsinized, 
washed with PBS, fixed in 4% paraformaldehyde, washed again, and resuspended in blocking 
buffer (TBS buffer, 0.1% Triton X-100, and 1% BSA) overnight at 4°C. The cell pellet was then 
washed, resuspended in unconjugated primary antibody for 1 hour at 4°C, washed, and 
resuspended in a secondary fluorescent-conjugated antibody for an additional 1 hour at 4°C.  
Cells were resuspended in blocking buffer and analyzed on a BD LSR II (Becton Dickinson 
Immunocytometry Systems, San Jose, CA) flow cytometer and FACSDiva software (Becton 
Dickinson Immunocytometry Systems, San Jose, CA).  Data was collected on 1x10
4
 cells.  
Double staining with primary antibodies against SSEA1 (Millipore MAB4301, Billerica, MA) 
and LIN28 (Abcam Inc. ab46020, Cambridge, MA) with respective FITC (SouthernBiotech 
1010-02, Birmingham, AL) and PerCP-Cy5.5 (Santa Cruz Biotechnologies sc-45101, Santa 
Cruz, CA) conjugated secondary antibodies was performed with resultant quadrant statistics 
including percentage of positive cells in each quadrant.  Calibration of the flow cytometer and 
 41 
 
setting of gates was performed using non-transduced P2 MEFs as negative controls and 
established 1-A4 (C57BL/6J x 129S1/SvlmJ) iPSCs and v6.4 (C57BL/6J x 129S4/SvJae) ESCs 
[28] as positive controls.  The 1-A4 iPSC line was generated in our laboratory and validated via 
teratoma formation in NOD.CB17-Prkdc
scid
/J mice and ability to generate germline chimeras 
through blastocyst injection.   
iPSC line generation: iPSC colonies from 6-well primary transformation plates were picked 
with pipette tips into individual wells of 96-well tissue culture plates containing trypsin.  The 
trypsin was neutralized with DMEM and 10% FBS, and the cells within each well were then 
transferred to individual wells of 96-well tissue culture plates seeded with feeder cells in ESC 
media and expanded.  Doxycycline was removed from the media at the 6-well plate stage 
(around P7) in order to establish doxycycline-independent cell lines from each strain.  The cells 
were then further expanded (P10-P15) in order to reach the cell numbers necessary for teratoma 
formation assays and for cryopreservation of stock from each strain. 
Teratoma formation and histological analysis: iPSCs from one doxycycline-independent cell 
line from each strain were trypsinized, pelleted and suspended at 1x10
7 
cells/mL in MEF media.  
150μl of the cell suspension (1.5x106 cells) was injected subcutaneously into the flank of a 
NOD.CB17-Prkdc
scid
/J mouse.  For each strain, a total of 6 injections were performed in 3 
NOD.CB17-Prkdc
scid
/J mice (both flanks of each mouse were injected).  Four to 5 weeks post 
injection, tumors were surgically dissected, fixed in 4% paraformaldehyde, embedded in 
paraffin, sectioned, and stained with hematoxylin and eosin. All histologic sections were 
reviewed by a board certified veterinary pathologist (T.L.S.) for teratoma formation. 
MEF proliferation assays: Proliferation of non-transduced parent P2 MEFs from each strain was 
examined every 2 days over a total of 10 days.  1.9x10
5
 MEFs were seeded on each 60mm tissue 
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culture plate to be cultured and later harvested at the indicated time points to perform cell counts.  
MEFs were maintained in standard MEF media for the first 24 hours and then the media was 
changed to ESC media supplemented with doxycycline to simulate reprogramming conditions 
for the remainder of the assay.  Assays were performed using MEFs derived from 2 different 
embryos for each strain. 
 
Results and Discussion 
Strain differences in efficiency to generate iPSCs are manifested in the early stages of 
reprogramming: In order to assess potential strain background effects on iPSC generation during 
early reprogramming, the primary transformation and 60mm plates were evaluated for the total 
number of colonies, the percentage of colonies positive for AP staining, and the percentage of 
cells positive for SSEA1 and LIN28 expression.  On both the 60mm plates in which the cells 
were used for AP staining and colony counting and the 6-well primary transformation plates in 
which the cells were used for flow cytometric analysis, gross differences in the generation of 
iPSC colonies were observed such that cells had to be stained and counted, or harvested for flow 
cytometry, after only 8 days of reprogramming in order to avoid overconfluency of cells from the 
most efficient strains (Figure 2.2A).  This time point was much earlier than expected based on 
the doxycycline-inducible lentiviral reprogramming system literature in which colonies are 
generally passaged or picked off of primary transformation plates around 13-21 days for 
expansion and/or evaluation [27, 29-30], and stresses the differences that can be observed when 
using strains of diverse genetic backgrounds.  Because the iPSCs were harvested at this very 
early time point of 8 days, the resultant LIN28 expression was negative in the iPSCs from all six 
strains and only SSEA1 expression was included in the final analysis.  This finding is consistent 
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Figure 2.2.  Strain differences during early iPSC reprogramming.  Gross strain differences in 
efficiency to generate iPSC colonies were observed after 8 days of MEF reprogramming as 
visualized in these photographs with alkaline phosphatase (AP) staining (A).  Strain differences 
were quantified by total number of colonies (B), percentage of colonies positive for alkaline 
phosphatase staining (C) and percentage of cells positive for SSEA-1 (D).  NON/LtJ and 
CAST/EiJ strains were consistently more efficient than other strains in generating early iPSCs.  
These differences were not believed to be due to strain differences in MEF transducibility, as 
demonstrated by the percentage of cells positive for GFP on day 8 following transduction with a 
lentiviral GFP vector (E).  Experiments were performed using MEFs derived from 2 different 
embryos for each strain (data presented as mean ± S.D.). 
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with the literature in which LIN28 is used as a marker for more established iPSCs and ESCs [31-
33] as confirmed by our control iPSC (1-A4) and ESC (v6.4) lines. 
During early reprogramming, MEFs from all of the strains formed cell colonies 
exhibiting typical iPSC morphology that were alkaline phosphatase (AP) positive within 8 days 
after the start of reprogramming.  However, the total number of colonies and the percentage of 
AP-positive colonies varied dramatically between the strains. Notably, NON/LtJ and CAST/EiJ 
strains were more efficient than other strains (Figures 2.2B and 2.2C).  Similarly, the percentage 
of cells positive for SSEA1 varied between the strains but paralleled the previous two parameters 
with NON/LtJ and CAST/EiJ having the highest percentage (Figure 2.2D).  As expected, the 
percentage of cells positive for SSEA1 was low (between 0.11 and 8.64%) at this early time 
point of 8 days after the start of reprogramming for all strains.  Using the same doxycycline-
inducible lentiviral reprogramming system, Brambrink et al. previously demonstrated that 
SSEA1 expression appears between 3 and 9 days of reprogramming, whereas AP activity 
appears within 3 days of reprogramming [27].  Brambrink et al. also showed that after 9 days of 
reprogramming, about 7% of AP-positive cells were also SSEA1-positive [27].  This percentage 
of SSEA1 positive cells is consistent with our findings. 
 To ensure that the differences amongst strains in reprogramming efficiency were not due 
to differences in lentiviral infection, P2 MEFs were seeded on 6-well plates at the same density 
as they were for reprogramming, transduced with a lentiviral GFP vector (Addgene 14883, 
Cambridge, MA) and maintained under reprogramming conditions.  After 8 days, the cells were 
trypsinized and the percentage of GFP positive cells was determined using flow cytometry.  The 
percentage of GFP positive cells was very similar for all strains, ranging from 35.10±5.23% for 
NON/LtJ MEFs to 51.25±0.21% for 129S1/SvImJ1 MEFs, suggesting that the strain differences 
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in efficiency to generate iPSCs were not due to strain differences in MEF transducibilty (Figure 
2E). 
Differences in proliferation of parent non-transduced MEFs correlate with differences in 
efficiency to generate iPSCs during early reprogramming: Proliferation of non-transduced 
parent P2 MEFs was examined every 2 days over a total of 10 days in order to determine if 
genetic differences in MEF proliferation could potentially be affecting the efficiency of iPSC 
generation (Figure 2.3A).  Strain differences in MEF proliferation were observed over the 10 
day period and a positive correlation was found between MEF growth rate and efficiency to 
generate iPSCs during early reprogramming.  This is demonstrated in Figure 2.3B where MEF 
growth rate and total number of colonies positive for AP staining are compared with a resultant 
r
2 
value of 0.75.  In particular, NON/LtJ and CAST/EiJ MEFs were the most proliferative and 
most efficient in generating iPSCs while DBA/2J MEFs were the least.   
 Interestingly, fibroblasts capable of increased proliferation through Trp53 deletion have 
increased iPSC generation efficiency [34-36].  It is possible that MEFs of the most efficient 
strains found in this study, NON/LtJ and CAST/EiJ, have a reduced rate of senescence compared 
to the other strains which is allowing for more effective reprogramming.  The fact that the most 
proliferative MEFs were of the CAST/EiJ strain is also of interest as this wild-derived inbred 
strain is the most genetically distinct strain that we examined.   
 The finding of this study that cellular proliferation rate is correlated with iPSC generation 
efficiency is consistent with those of Ruiz et al. in which the induction of cellular proliferation 
(through downregulation of pRb) increased human iPSC reprogramming efficiency [36].  In that 
study, Ruiz et al. also elegantly demonstrated that cell cycle arrest (through induction of the 
arrest inducers p15, p16, or p21) inhibits reprogramming and actually drives iPSCs towards 
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Figure 2.3.  Strain differences in MEF proliferation.  Strain differences in MEF proliferation 
were observed over 10 days and were well correlated with the observed strain differences in 
efficiency to generate iPSCs during early reprogramming.  Non-transduced parent P3 MEFs 
from each strain were seeded at 1.9x10
5
 cells per 60mm tissue culture plate on Day 0 and then 
counted every 2 days over a total of 10 days (A).  MEFs were maintained in standard MEF 
media for the first 24 hours after which the media was changed to ESC media supplemented with 
doxycycline to simulate reprogramming conditions.  MEFs derived from 2 different embryos 
were evaluated for each strain and (data presented as mean ± S.D.).  The growth rate of the 
MEFs from each strain was determined from the slope of the linear regression curve fitted to the 
data set in (A) for each strain.  The growth rate of each strain was then plotted against the total 
number of colonies positive for AP staining and a line of best fit determined, revealing a 
moderately strong positive correlation between iPSC generation efficiency and MEF 
proliferation as indicated by the r
2
 value (B). 
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irreversible differentiation [37].  A potential follow-up study to this one in order to further 
elucidate the mechanisms behind the differences in genetic background effects on iPSC 
efficiency would be to alter the cellular proliferation of the MEFs for each strain, either through 
induction or arrest, and then examine the iPSC generation efficiency. 
BALB/cJ iPSCs require a higher concentration of LIF than other strains for cell line 
expansion and doxycycline independence: In order to determine if genetic background affects 
the pluripotent stability of iPSCs during later stages of reprogramming, iPSC lines from all six 
strains were established and further expanded without doxycycline supplementation.  
Doxycycline-independent iPSC lines could be established using our standard conditions and ESC 
media for all strains except BALB/cJ, which were established only when supplemented with a 
higher concentration (5x) of LIF. This finding suggests that BALB/cJ iPSCs may have reduced 
pluripotent stability and is consistent with the BALB/cJ ESC literature in which BALB/cJ ESC 
lines were established only when using a 5x higher concentration of LIF than that needed for 
other strains [5-7].  The mechanism behind this requirement for increased LIF supplementation 
in BALB/cJ cells has yet to be identified. 
Doxycycline-independent cell lines from all strains are capable of producing teratomas in 
SCID mice: Doxycycline-independent cell lines from all the strains were capable of producing 
teratomas in NOD.CB17-Prkdc
scid
/J mice by 5 weeks post injection, thereby demonstrating 
pluripotency (Figure 2.4).  For all strains, the cell lines were between P10 and P15 and were the 
initial cell lines chosen for the teratoma assay.  None of the cell lines from any of the strains 
required a repeat set of injections or the assay to be repeated with a different cell line.   
 iPSC lines in this study were not evaluated for their ability to generate chimeras or for 
germline competence, making direct comparison to the ESC literature on the effect of genetic 
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Figure 2.4.  Pluripotency of iPSCs derived from MEFs of each strain.  Doxycycline-independent 
cell lines from all the strains were capable of producing teratomas in NOD SCID mice by 5 
weeks post injection as shown in these histologic images, all of which are stained with 
hematoxylin and eosin and viewed at 200x magnification.  (A) = NON/LtJ; (B) = C57BL/6J; (C) 
= DBA/2J; (D) = BALB/cJ; (E) = 129S1/SvlmJ; (F) = CAST/EiJ.  Tissues from all three germ 
layers were identified on each section as indicated by the labels: Ect = Ectoderm; Mes = 
Mesoderm; End = Endoderm. 
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background difficult beyond the finding of reduced pluripotent stability already discussed for the 
BALB/cJ strain.  While the 129S1/SvlmJ strain was moderately efficient in generating IPSCs 
compared to the other strains in this study and the 129S1/SvlmJ iPSC line was readily able to 
form teratomas in NOD.CB17-Prkdc
scid
/J mice, a conclusion cannot be drawn from this data as 
to whether or not this strain is as useful for generating iPSCs as it has been shown to be for 
generating ESCs for transgenic applications [6,7].  In addition, the two most efficient strains in 
this study, NON/LtJ and CAST/EiJ, are strains which have not been examined for their ability to 
generate ESCs, making them intriguing candidates for future studies. 
 
Conclusions 
 Our comparison of six different inbred mouse strains has revealed that genetic 
background does affect both the efficiency of generating iPSCs during the early stages of 
reprogramming as well as the pluripotent stability of the cells during later stages of 
reprogramming.  These findings suggest that genetic background must be considered when 
interpreting results of iPSC studies in the literature and that iPSC derivation may need to be 
customized for different strains.  In addition, our findings suggest that the proliferation rate of 
the fibroblasts is positively correlated with iPSC generation, suggesting a possible simple 
laboratory screening parameter to predict iPSC generation efficiency. 
The two most efficient strains in this study, NON/LtJ and CAST/EiJ, may prove useful in 
the future for deriving iPSCs for transgenic purposes, as iPSCs from these strains appear to be 
robust.  One limitation to this study, however, was that we did not evaluate the iPSCs lines for 
their ability to generate chimeras and for germline competence.  This information is essential for 
ultimately determining which strain may be most beneficial for transgenic applications.   
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In conclusion, we have shown that there are strain differences in efficiency to generate 
iPSCs during the early stages of reprogramming and that these strain differences are correlated 
with those observed in proliferation of parent MEFs.  We have also shown that there are strain 
differences in pluripotent stability as far as ability to expand iPSC lines and achieve doxycycline 
independence.  These findings have important implications both for future iPSC applications as 
well as for future investigation into determining the genes responsible for reprogramming 
efficiency and stability.  It is possible that the Collaborative Cross, of which three of the strains 
examined in this study are progenitors, could be used to identify such genes. 
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Abstract 
  The immunogenic properties of induced pluripotent stem cells (iPSCs) are currently 
being investigated.  Clinically, banked iPSCs will be necessary for most applications due to the 
extended time period needed to generate iPSCs and to screen them for efficacy and safety.  In 
addition, autologous iPSC therapy may not be possible for some individuals because of the 
influence of genetic background on iPSC generation.  The immunogenic and immunomodulatory 
properties of mesenchymal stem cells (MSCs) are investigated for many of the same reasons and 
it has been demonstrated that they possess significant immunomodulatory properties. The 
purpose of this study was to evaluate the in vitro immunogenic and immunomodulatory 
properties of iPSCs compared to adult bone marrow-derived MSCs using modified mixed 
leukocyte reactions. Our comparisons revealed that iPSCs generated through both lentiviral and 
piggyBac reprogramming methods had similar immunogenic properties as MSCs but had more 
potent immunomodulatory effects than MSCs.  Co-culture of MHC-mismatched leukocytes with 
MHC-matched iPSCs resulted in significantly less responder T cell proliferation than observed 
for MHC-mismatched leukocytes alone and at more responder leukocyte concentrations tested 
than was observed for co-culture of MHC-mismatched leukocytes with MHC-matched MSCs.  
In addition, MHC-mismatched iPSCs were able to significantly reduce responder T cell 
proliferation when co-cultured with MHC-mismatched leukocytes, while MHC-mismatched 
MSCs were not.  These results provide important information when considering the use of iPSCs 
in place of MSCs in both regenerative and transplantation medicine.   
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Introduction 
 Upon their creation in 2006, induced pluripotent stem cells (iPSCs) were regarded as the 
most promising stem cell candidate for the clinical application of regenerative therapies [1-3]. 
iPSCs are pluripotent, unlike mesenchymal stromal cells (MSCs), and can be used autologously, 
unlike pluripotent embryonic stem cells (ESCs). Additionally, iPSCs avoid the ethical concerns 
surrounding the isolation and use of human ESCs [4].  Since that time, however, many concerns 
have been raised over the safety of iPSCs in terms of genetic instability, tumorigenic potential, 
and immunogenic potential [4-9].  It has become evident that iPSC lines must be thoroughly 
screened for stability, safety, and efficacy prior to clinical application [7].  Such screening, after 
an already lengthy generation process, makes autologous iPSC use impractical for many of 
diseases that would potentially benefit from stem cell therapy.  In addition, it has been 
demonstrated that genetic background affects iPSC generation, suggesting that autologous iPSC 
therapy may not be feasible for some patient regardless of timing issues [10].  For these reasons, 
the immunogenicity of iPSCs is of particular concern as the need for having a bank of previously 
screened cells has become a reality [7, 11].  
 In a similar interest of having cells available at the time of diagnosis for immediate 
treatment, the immunogenic and immunomodulatory properties of MSCs have been, and 
continue to be investigated [12-18].  It has also been demonstrated that both genetic background 
and age of the patient affect proliferation and differentiation rates of MSCs, suggesting that 
allogeneic MSC therapy may be required for some patients as is possible for iPSCs [19-21].  
Adult MSCs have low immunogenicity when used autologously and possess significant 
immunomodulatory properties [13, 15, 22-25].  Many mechanisms for the immunosuppressive 
effects of MSCs have been described including inhibition of T cell proliferation, alteration of  
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dendritic cell maturation, induction of regulatory lymphocytes, and apoptosis of CD8 positive T 
cells [15, 22, 26-28].  While it was initially believed and demonstrated that allogeneic MSCs are 
immune privileged due to these immunosuppressive properties [29-32], immune rejection of 
allogeneic MSCs has also been reported [33-38].   The finding that MSCs are capable of 
alterations in their MHC class I and II expression profiles is likely to blame for these conflicting 
results.  While adult MSCs generally display the phenotype of high MHC class I expression and 
low or negative MHC class II expression, MSCs from mice, humans, and more recently horses 
with high MHC II expression levels have also been described [33, 34, 39, 40].  Additionally, 
both MHC class I and class II expression levels on MSCs can be upregulated by 
proinflammatory cytokines such as IFN-ɣ [41, 42]. 
 Investigation into the immunogenic properties and immune plasticity of iPSCs has just 
recently begun [7, 11, 43-45].  It is known that undifferentiated iPSCs, like ESCs, express low or 
absent levels of MHC class I and are negative for MHC class II expression [46].  Interestingly, 
MHC class II expression is not upregulated by differentiation or by stimulation with IFN-ɣ [46-
48]. The extent to which MHC class I expression can change upon iPSC differentiation or 
stimulation with proinflammatory cytokines, however, is incompletely understood.  Several 
studies have shown that MHC class I expression increases upon iPSC differentiation and with 
IFN-ɣ stimulation, but often only to a level still much less than that of somatic cells [44, 46].  
The consequence of such a change in MHC class I expression is complex as a high expression 
level of MHC class I could lead to T cell activation while a continued lack of MHC class I 
expression could potentially lead to iPSCs being targeted by natural killer (NK) cells in vivo [6].  
Conflicting results have been reported for ESCs on this subject, with some groups reporting 
ESCs as susceptible to NK cell lysis, and others reporting that ESCs are neither susceptible to 
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NK cell lysis nor capable of eliciting T cell responses [6, 49].  It is likely that culture conditions 
or differences in ESC lines could have affected these results.   
 It is not surprising that conflicting results have also been reported on the immunogenicity 
of iPSCs, as iPSCs are in many ways more variable than ESCs, particularly due to discrepancies 
in reprogramming methods including viral vs. non-viral and integrating vs. non-integrating [43-
45, 47, 50, 51].  While the first report on the immunogenicity of iPSCs revealed that 
undifferentiated autologous (syngeneic) mouse iPSCs were immune rejected in a teratoma model 
study [43], two other reports since then have shown that both undifferentiated and differentiated 
syngeneic mouse iPSCs are non-immunogenic in vitro and in vivo [44, 45].  To date, no studies 
have examined the immunomodulatory properties of iPSCs even though it is known that ESCs 
are capable of immunosuppression through multiple mechanisms including expression of 
arginase I [47, 52], prevention of dendritic cell maturation [53], and upregulation of regulatory T 
cells [47, 54].  When considering the use of iPSCs as an alternative for MSC therapy, this 
information is critical.  The purpose of this study, therefore, was to evaluate the in vitro 
immunogenic and immunomodulatory properties of iPSCs compared to adult bone marrow-
derived MSCs using modified mixed leukocyte reactions.  Our hypothesis, based on prior ESC 
knowledge, was that undifferentiated iPSCs would have similar immunogenic and immodulatory 
properties as MSCs.   
 
Materials and Methods 
Mice: Male and female mice of the C3HeB/FeJ (MHC H2 haplotype k) and C57BL/6J (MHC H2 
haplotype b) inbred strains were purchased from The Jackson Laboratory (Bar Harbor, ME).  For 
each strain, mice were bred to produce offspring needed to harvest different cell types and 
 63 
 
perform experiments. NOD.CB17-Prkdc
scid
/J mice, used for teratoma formation assays, were 
also purchased from The Jackson Laboratory (Bar Harbor, ME).  The use of mice in this study 
was approved by the Institutional Animal Care and Use Committee of Cornell University. 
Mouse embryonic fibroblast (MEF) isolation:  Embryonic day 13.5 C3HeB/FeJ and C57BL/6J 
embryos were collected and processed to generate mouse embryonic fibroblasts (MEFs) from 
each strain as previously described [10].  MEFs were cultured in MEF media (high glucose 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% Fetal Bovine Serum (FBS), 
penicillin (100 units/mL), and streptomycin (100μg/mL)) and cryopreserved at passage 1 (P1) to 
be used for iPSC generation and at P2 to be used as controls in MLR experiments.  MEFs to be 
used as feeder cells from each strain were culture expanded, irradiated with 30 Gy from a Cs-137 
source, and cryopreserved. 
Lentiviral reprogramming of MEFs: Lentiviral supernatant generation and reprogramming of 
MEFs was performed as previously described by our laboratory [10] using vectors for 
doxycycline-inducible transgene expression of the mouse factors Oct4, Sox2, Klf4 and c-Myc.  
All plasmids were purchased from Addgene (Cambridge, MA).  Briefly, P1 MEFs from each 
strain were thawed and cultured in MEF media for 24-48 hours, after which they were 
trypsinized and counted.  The P2 MEFs were seeded onto gelatin-coated 6-well tissue culture 
plates at a density of 6.75x10
3
 cells/cm
2
 in MEF media and allowed to adhere for 24 hours.  The 
culture media was then replaced with fresh MEF media supplemented with viral supernatant for 
an additional 24 hours.   Following incubation with viral media, MEFs were trypsinized and 
passaged onto 60mm tissue culture plates seeded with feeder cells of the same strain.  Culture 
media at this time was changed to ESC media (KnockOut
TM
 DMEM (Gibco, Grand Island, NY) 
supplemented with 15% KnockOut
TM
 Serum Replacement (Gibco, Grand Island, NY), 
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recombinant LIF, MEM non-essential amino acids solution (100µm), 2mM GlutaMAX
TM
 
(Gibco, Grand Island, NY), 0.1 mM 2-Mercaptoethanol, penicillin (100 units/mL), streptomycin 
(100μg/mL), and doxycycline (2µg/mL; Sigma, St. Louis, MO)).  ESC media was refreshed 
daily during reprogramming.     
PiggyBac reprogramming of MEFs: P2 MEFs were transfected with the Nucleofector
®
 II 
electroporation device (Amaxa Biosystems, Gaithersburg, MD) set on program A-023.  Each 
electroporation was performed in a 2mm cuvette (Amaxa Biosystems, Gaithersburg, MD) with 
2x10
6
 cells and a DNA mixture of 1μg each of the piggyBac plasmids PB-TET-MKOS, PB-
CAG-rtTA, and PB-CAG-GFP (kindly provided by the laboratory of Dr. Nagy [55]) as well as 
1μg of the transposase expression vector pCyL43 (Wellcome Trust Sanger Institute, Cambridge, 
UK) in a total volume of 100μL Ingenio® electroporation solution (Mirius Bio, Madison, WI).  
Following electroporation, cells from each cuvette were seeded onto a 100mm tissue culture 
plate in MEF media.  After 24 hours, culture media was changed to ESC media. 
iPSC line generation: Lentiviral and piggyBac iPSC colonies were picked with pipette tips and 
culture expanded on feeder cells in ESC media as previously described [10].  Lentiviral iPSC 
colonies were picked on day 7-11 of reprogramming, while piggyBac iPSC colonies were picked 
on day 17-22 post-transfection.  Doxycycline was removed from the media around P7 and 
doxycycline-independent cell lines were then further expanded (P10-P12) in order to reach the 
cell numbers necessary for teratoma formation assays and cryopreservation of stock from each 
strain.  In preparation for MLR experiments, iPSC cell lines from each strain were then further 
cultured in modified RPMI 1040 media containing 10% FBS, 0.1 mM 2-Mercaptoethanol, 
penicillin (100units/mL), streptomycin (100μg/mL), and ESGRO® LIF (1uL/mL; Millipore, 
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Billerica, MA).  Following this transition to modified RPMI 1040 media, teratoma assays were 
again performed. 
Teratoma formation and histological analysis: iPSC lines from each strain were trypsinized, 
pelleted and suspended at 1x10
7 
cells/mL in a 1:3 solution of Matrigel
TM
 (BD Biosciences, San 
Jose, CA) to MEF media.  150μl of the cell suspension (1.5x106 cells) was injected 
subcutaneously into the flank of a NOD.CB17-Prkdc
scid
/J mouse.  For each cell line, a total of 2-
4 injections were performed.  Four to 5 weeks post injection, tumors were surgically dissected, 
fixed in 4% paraformaldehyde, embedded in paraffin, sectioned, and stained with hematoxylin 
and eosin. All histologic sections were reviewed by a board certified veterinary pathologist 
(T.L.S.) for teratoma formation. 
Bone marrow harvest and isolation of MSCs: Ten female mice 3-6 weeks of age from each 
strain were euthanized, prepared with ethanol, and processed for bone marrow harvest according 
to a protocol kindly provided by the laboratory of Dr. Rocky S. Tuan.  Briefly, the hindlimbs 
were skinned, disarticulated from the pelvis, and placed in a petri dish with MEMα media with 
nucleosides and L-glutamine (Gibco, Grand Island, NY) containing 10% FBS, penicillin 
(100units/mL), streptomycin (100μg/mL), and Fungizone® (0.25μg/mL; Gibco, Grand Island, 
NY).  All muscle and tissue was removed from the bone using a scalpel blade and placed in a 
second petri dish with phosphate buffered saline (PBS).  Next, the ends of the long bones were 
cut off so that the marrow cavity was exposed.  The marrow cavity of each bone was then 
flushed with MEMα media using a 27g needle and 12mL syringe into an empty petri dish.  The 
bone marrow cell suspension was then passed through a 70μm cell strainer (BD Biosciences, San 
Jose, CA), pellets, resuspended in red blood cell lysis buffer (0.84% NH4Cl), and incubated for 2 
minutes on ice.  Following the incubation, cells were washed with MEMα media, counted, and 
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seeded at 25x10
6
 cells/mL onto 100mm tissue culture plates with MEMα media.  After 5 hours in 
the incubator, the media was removed, the plates gently washed to remove non-adherent cells, 
and new MEMα media containing FGF-2 (5ng/mL) added.  For the next 72 hours, media 
exchange occurred every 12 hours; afterwards media exchange occurred every 72 hours.  When 
the cells were approximately 80% confluent, they were trypsinized at room temperature for 2 
minutes, counted, and seeded at 5,000 cells/cm
2
 onto T-75 flasks with MEMα media containing 
FGF-2 (5ng/mL).  The cells were then expanded to P2 and P3 and stocks were cryopreserved for 
immunophenotyping and MLR experiments.   
Immunophenotyping of MEFs, iPSCs, and MSCs: 
MEFs, iPSCs, and MSCs were immunophenotyped for expression levels of MHC class I and 
MHC class II.  MSCs were additionally phenotyped for a panel of positive (CD4, CD29) and 
negative (CD45, CD117) markers using flow cytometry [56-58].  MHC class I (rat anti-mouse; 
PE-conjugated), MHC class II (rat ant-mouse; PE-Cy5-conjugated), and CD29 (hamster anti-
mouse; PE-conjugated) antibodies were purchased from eBioscience (Affymetrix, Santa Clara, 
CA).  CD44 (rat anti-mouse; FITC-conjugated), CD45 (rat anti-mouse; PerCP-Cy5.5), and 
CD117 (rat anti-mouse; APC-conjugated) antibodies were purchased from BD Biosciences (San 
Jose, CA).  Cells were pelleted in aliquots containing approximately 1x10
6
 cells on 96-well V-
bottom plates and treated with a 10 min blocking step using anti-mouse CD16/CD32 (Fc 
Block
TM
; BD Biosciences, San Jose, CA) at 1:100 in PBS. The cells were pelleted and 
resuspended in conjugated primary antibody and incubated for 45 min at 4°C. Cells were then 
washed, resuspended in PBS and analyzed on a FACSCalibur (Becton Dickinson 
Immunocytometry Systems, San Jose, CA) flow cytometer equipped with 488 μm argon and 635 
μm red diode lasers and BD Cell Quest™ analysis software (BD Biosciences, San Jose, CA). 
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Cells exposed to appropriately conjugated rat or hamster IgG was used as negative isotype 
controls.  Data were collected on 2x10
4
 cells for each sample. 
Splenocyte isolation and leukocyte purification: Spleens were aseptically harvested from 
C3HeB/FeJ and C57BL/6J female mice 6-12 weeks of age and dissociated in RPMI 1040 media 
(Gibco, Grand Island, NY)  using a cell dissociation sieve equipped with a 40 mesh screen 
(Sigma-Aldrich, St. Louis, MO). The resultant splenocyte suspension was then passed through a 
100μm cell strainer (BD Biosciences, San Jose, CA), pelleted, resuspended in red blood cell lysis 
buffer (0.84% NH4Cl) and incubated for 5 minutes at room temperature with rocking. Following 
red blood cell lysis, the suspension was washed with PBS, pelleted, and purified using 
Lympholyte
®
-M density gradient centrifugation (Cedarlane Laboratories, Burlington, NC) 
according to the manufacturer directions to obtain leukocytes. Cells destined to be stimulator 
leukocytes in mixed leukocyte reactions were aliquoted at this time.  The remaining leukocyte 
suspension was then plated onto 100mm tissue culture plates in RPMI 1040 medium (Gibco, 
Grand Island, NY) containing 10% fetal bovine serum (FBS), 0.1 mM 2-Mercaptoethanol, 
penicillin (100 units/mL) and streptomycin (100units/mL).  After 2 hours, the non-adherent cells 
were removed from the plates, pelleted, and counted.  Non-adherent leukocytes then underwent 
positive selection for CD62L, a naïve T cell marker [59-62], using MACS CD62L microbeads 
and LS columns (Miltenyi Biotec, Auburn, CA) according to the manufacturer directions.  
Adherent leukocytes (containing antigen presenting cells (APCs)) were dissociated using 
Accumax® cell dissociation solution (Innovative Cell Technologies Inc, SanDiego, CA), 
counted, and aliquoted.  All leukocytes were used fresh in mixed leukocyte reactions. 
Modified one-way mixed leukocyte reactions (MLRs): Modified one-way mixed leukocyte 
reactions (MLRs) were performed in duplicate on 24-well tissue culture plates using MHC-
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matched and mismatched C3HeB/FeJ responder leukocytes and C3HeB/FeJ and C57BL/6J 
stimulator leukocytes, MEFs, iPSCs, and MSCs.  In order to assess the immunogenic potential of 
the cells, MEFs, iPSCs, and MSCs were used as stimulator cells for responder leukocytes.  In 
order to assess the immunomodulatory properties of the cells, MEFs, IPSCs, and MSCs were 
cultured in the presence of stimulator and responder leukocytes.  MHC-matched stimulator 
leukocytes were used to establish baseline T cell proliferation and MHC-mismatched stimulator 
leukocytes were used as positive MLR controls. MEFs were considered the negative control in 
the immunomodulatory potential studies.  C3HeB/FeJ responder leukocytes were labeled with 
5(6)-carboxyfluorescein diacetate N-succinimidyl ester (CFSE (0.13μg/ml, Sigma-Aldrich, St. 
Louis, MO) and examined at 4 different concentrations (2x10
5
, 4x10
5
, 8x10
5
, and 1.2x10
6
 
cells/well).  Proliferative ability of responder cells was verified via mitogen stimulation with 
phytohemaglutinin (PHA-P (5μg/ml, Sigma-Aldrich, St. Louis, MO)).   Stimulator MEFs, iPSCs, 
and MSCs were plated 24 hours prior to the addition of responder leukocytes in their appropriate 
media such that all cells would be approximately 80% confluent by the end of the experiment.  
MEFs were seeded at 1x10
4
 cells/well, iPSCs (removed from feeders) at 7.5x10
4
 cells/well, and 
MSCs at 3x10
4
 cells/well.  Stimulator leukocytes were irradiated with 9 Gy from a Cs-137 
source to inhibit proliferation and plated at 1.6x10
6
 cells/well. Responder APCs (adherent cells 
during isolation) were plated at 1x10
5
 cells/well.  Importantly, responder leukocytes and APCs 
were mixed with stimulator leukocytes prior to plating due to concern that the 3-dimensional 
nature of the iPSC colonies could interfere with responder and stimulator cell contact. The 
resultant ratios of responder:stimulator cells was based on previously published experimental 
protocols  and determined to be optimal for these studies in preliminary experiments [63-65]. 
Cultures were maintained for 5 days with modified RPMI 1040 media (1.5 mL/well) containing 
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10% FBS, 0.1mM 2-Mercaptoethanol, penicillin (100units/mL), streptomycin (100μg/mL), and 
ESGRO® LIF (1uL/mL; Millipore, Billerica, MA).  Media were not exchanged over the 5 days.  
Following culture, leukocytes were aspirated from the wells and stained with a hamster anti-
mouse APC-conjugated CD3 antibody (Abcam, Cambridge, MA).  The antibody staining process 
for flow cytometry analysis was performed as described above for immunophenotyping.  
 Proliferation of gated CFSE-labeled CD3-positive responder T cells was evaluated via 
CFSE attenuation using flow cytometry.  Cells were first gated on FL4 so that only the CD3-
positive cells (T cells) were then examined on FL1 for CFSE attenuation. Non-stimulated 
responder T cells were used to set the boundary of non-proliferating cells such that all cells to the 
left (lower fluorescence intensity on FL1) of that boundary were determined to be proliferating.  
Because the number of cell counts in the proliferating T cell gate was measured, data was 
collected on the entirety of each sample. 
 MLRs were performed in a total of 2 experiments.  MEFs from 2 different embryos of 
each strain were tested in addition to 2 iPSC lines (1 lentiviral and 1 piggyBac) from each strain 
and batched MSCs from each strain.  Due to naturally occurring variation in leukocyte responses 
between mice and experiments, the relative T cell proliferation was reported as the fold change 
from that of the MHC-matched MLR for the immunogenic potential experiments (i.e. looking for 
an increase from baseline T cell proliferation potential if immunogenic) and as the fold change 
from that of the MHC-mismatched MLR for the immunomodulatory potential experiments (i.e. 
looking for a decrease from positive control T cell proliferation towards the baseline T cell 
proliferation if immunomodulatory).  For the immunomodulatory potential experiments, data 
were also reported as the percentage proliferation of that of the MHC-mismatched MLR. 
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Statistical analyses: MLR data for lentiviral and piggyBac iPSC lines were first compared using 
two-sample t-tests. All MLR data were normalized by long transformation and analyzed with 
analysis of covariance (ANCOVA), with experiment as a covariate, followed by the Tukey test 
for multiple comparisons. All analyses were performed using Statistix 9 software (Analytical 
Software, Tallahassee, FL) and significance was set at P < 0.05. 
 
Results 
iPSC line generation and validation: Multiple doxycycline-independent lentiviral and piggyBac 
iPSC lines were established from each strain and early passage stocks were cryopreserved.  One 
doxycycline-independent lentiviral iPSC line and 1 doxycycline piggyBac iPSC line from each 
strain was tested after expansion in ESC media and then again after expansion in modified RPMI 
1040 media.  These lines were capable of producing teratomas in NOD.CB17-Prkdc
scid
/J mice by 
5 weeks post injection, thereby confirming pluripotency and lack of alteration due to the change 
in media. 
Immunophenotyping:  MEFs had a phenotype of MHC class I positive (low) and MHC class 
negative, while iPSCs had a phenotype of both MHC class I and class II negative.  MSCs were 
positive for expression of MHC class I, CD44, and CD29 and negative for expression of MHC 
class II, CD45, and CD117. 
Modified one-way mixed leukocyte reactions (MLRs): There were no significant differences in 
responder T cell proliferation when stimulated by lentiviral iPSCs or piggyBac iPSCs, or when 
stimulated by MHC-mismatched leukocytes in the presence of lentiviral iPSCs or piggyBac 
iPSCs (as determined by two-sample t-tests with significance set at P < 0.05).  The cells were 
therefore considered one group and are collectively referred to as iPSCs for the remainder of the 
results. 
 71 
 
 As predicted based on MHC class II expression, all of the cell types tested (MEFs, iPSCs, 
and MSCs) had low immunogenicity when either MHC-matched or MHC-mismatched with the 
responder leukocytes (Figures 3.1 and 3.2).  MSCs resulted in the highest levels of responder T 
cell proliferation compared to MEFs and iPSCs, particularly when MHC-mismatched, but these 
levels were not significantly different from MEFs or iPSCs at any of the responder leukocyte 
concentrations tested, even when statistically equivalent to the positive control of MHC-
mismatched leukocytes (Figures 3.2A and 3.2G). 
 Both iPSCs and MSCs cultured in the presence of MHC-mismatched responder and 
stimulator leukocytes (MHC-mismatched MLR) resulted in reduction of responder T cell 
proliferation from that observed for the MHC-mismatched MLR alone towards the baseline 
proliferation value observed for the MHC-matched MLR (Figures 3.3 and 3.4).  This reduction 
of responder T cell proliferation was greatest when the iPSC and MSCs were MHC-matched 
with the responder leukocytes compared to when MHC-mismatched with responder leukocytes. 
MHC-matched iPSCs resulted in significantly decreased responder T cell proliferation compared 
to both the MHC-mismatched MLR and the negative control of MEFs at the 3 highest responder 
leukocyte concentrations (Figures 3.4B - 3.4D).  While MHC-matched MSCs resulted in 
statistically equivalent responder T cell proliferation compared to iPSCs for the same 3 
responder leukocyte concentrations, mean T cell proliferations were greater than for iPSCs and 
in some cases also equivalent to the MHC-mismatched MLR and/or the negative control of 
MEFs (Figures 3.4B - 3.4D).  When MHC-mismatched cell types were evaluated, only iPSCs 
were able to reduce responder T cell proliferation significantly from the MHC-mismatched MLR 
at the responder leukocyte concentration of 8x10
5
 cells (Figure 3.4G). Once again, while MHC-
mismatched MSCs resulted in statistically equivalent responder T cell proliferation
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Figure 3.1. Immunogenicity of  MHC-matched (A) and MHC-mismatched (B) MEFs, iPSCs, 
and MSCs as determined by responder T cell proliferation in modified one-way mixed leukocyte 
reactions.  Data are presented as the log fold change of the MHC-matched MLR which was 
considered the baseline responder T cell proliferation value.  Bars represent mean ± S.D. from a 
total of 2 separate experiments performed with multiple cell lines.  MHC-M = MHC-matched; 
MHC-MM = MHC-mismatched.  None of the cell types tested approached the responder T cell 
proliferation of that of the positive control of MHC-mismatched leukocytes (MHC-MM MLR).  
Statistical data is shown in Figure 3.2. 
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Figure 3.2.  Modified one-way mixed leukocyte reaction (MLR) results for MHC-matched cells 
(A-D) and MHC-mismatched cells (E-H) at the different responder leukocyte concentrations 
tested.  Bars represent mean ± S.D. from a total of 2 separate experiments performed with 
multiple cell lines. Superscript letters indicate significant differences between groups by 
ANCOVA, with experiment as a covariate, followed by the Tukey test for multiple comparisons, 
P < 0.05.  MHC-M = MHC-matched; MHC-MM = MHC-mismatched.  MSCs resulted in the 
highest levels of responder T cell proliferation compared to MEFs and iPSCs, particularly when 
MHC-mismatched, but these levels were not significantly different from MEFs or iPSCs at any 
of the responder leukocyte concentrations tested, even when statistically equivalent to the 
positive control of MHC-mismatched leukocytes (A and G). 
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Figure 3.3. Immunomodulatory ability of  MHC-matched (A) and MHC-mismatched (B) MEFs, 
iPSCs, and MSCs as determined by responder T cell proliferation in modified one-way mixed 
leukocyte reactions with the cell types in the presence of MHC-mismatched responder and 
stimulator leukocytes.  Data are presented as the log fold change from that of the MHC-
mismatched MLR.  Bars represent mean ± S.D. from a total of 2 separate experiments performed 
with multiple cell lines.  MHC-M = MHC-matched; MHC-MM = MHC-mismatched.  Both 
iPSCs and MSCs were able to reduce responder T cell proliferation towards that of the MHC-
matched MLR, while MEFs (negative control) did not.  Statistical data is shown in Figure 3.4. 
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Figure 3.4. Modified one-way mixed leukocyte reaction (MLR) results for MHC-matched cells 
(A-D) and MHC-mismatched cells (E-H) cultured in the presence of MHC-mismatched 
responder and stimulator leukocytes at the different responder leukocyte concentrations tested.  
Data are presented as the percentage proliferation of that of the MHC-mismatched MLR alone.  
Bars represent mean ± S.D. from a total of 2 separate experiments performed with multiple cell 
lines. Superscript letters indicate significant differences between groups by ANCOVA, with 
experiment as a covariate, followed by the Tukey test for multiple comparisons, P < 0.05.  MHC-
M = MHC-matched; MHC-MM = MHC-mismatched.  MHC-matched iPSCs resulted in 
significantly decreased responder T cell proliferation compared to both the MHC-mismatched 
MLR and the negative control of MEFs at the 3 highest responder leukocyte concentrations (B-
D). Only iPSCs were able to reduce responder T cell proliferation significantly from the MHC-
mismatched MLR at the responder leukocyte concentration of 8x10
5
 cells (G).   
 79 
 
 
2
x
1
0
5
 R
e
s
p
o
n
d
e
r 
L
e
u
k
o
c
y
te
s
MHC-MM MLR
MHC-M MEF
MHC-M iPSC
MHC-M MSC
Relative T Cell Proliferation 
 (Percentage of MHC-MM MLR)
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
2
2
0
2
4
0
A
A
A
A
A
 
4
x
1
0
5
 R
e
s
p
o
n
d
e
r 
L
e
u
k
o
c
y
te
s
MHC-MM MLR
MHC-M MEF
MHC-M iPSC
MHC-M MSC
Relative T Cell Proliferation 
 (Percentage of MHC-MM MLR)
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
A
A
B
C
B
C
B
 
8
x
1
0
5
 R
e
s
p
o
n
d
e
r 
L
e
u
k
o
c
y
te
s
MHC-MM MLR
MHC-M MEF
MHC-M iPSC
MHC-M MSC
Relative T Cell Proliferation 
 (Percentage of MHC-MM MLR)
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
A
A
B
A
B
C
 
1
.2
x
1
0
6
 R
e
s
p
o
n
d
e
r 
L
e
u
k
o
c
y
te
s
MHC-MM MLR
MHC-M MEF
MHC-M iPSC
MHC-M MSC
Relative T Cell Proliferation 
 (Percentage of MHC-MM MLR)
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
A
B
B
A
D
 
2
x
1
0
5
 R
e
s
p
o
n
d
e
r 
L
e
u
k
o
c
y
te
s
MHC-MM MLR
MHC-MM MEF
MHC-MM iPSC
MHC-MM MSC
Relative T Cell Proliferation 
 (Percentage of MHC-MM MLR)
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
A
A
A
A
E
 
4
x
1
0
5
 R
e
s
p
o
n
d
e
r 
L
e
u
k
o
c
y
te
s
MHC-MM MLR
MHC-MM MEF
MHC-MM iPSC
MHC-MM MSC
Relative T Cell Proliferation 
 (Percentage of MHC-MM MLR)
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
A
A
A
A
F
 
8
x
1
0
5
 R
e
s
p
o
n
d
e
r 
L
e
u
k
o
c
y
te
s
MHC-MM MLR
MHC-MM MEF
MHC-MM iPSC
MHC-MM MSC
Relative T Cell Proliferation 
 (Percentage of MHC-MM MLR)
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
A
A
B
A
B
G
 
1
.2
x
1
0
6
 R
e
s
p
o
n
d
e
r 
L
e
u
k
o
c
y
te
s
MHC-MM MLR
MHC-MM MEF
MHC-MM iPSC
MHC-MM MSC
Relative T Cell Proliferation 
 (Percentage of MHC-MM MLR)
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
A
A
A
A
H
 
P
 =
 0
.3
0
 
P
 ˂
 0
.0
1
 
P
 ˂
 0
.0
1
 
P
 =
 0
.1
4
 
P
 =
 0
.0
7
 
P
 =
 0
.0
2
 
P
 ˂
 0
.0
1
 
P
 =
 0
.3
9
 
 80 
 
compared to iPSCs at this concentration, the mean T cell proliferation was greater than for iPSCs 
and also equivalent to that of MEFs (Figures 3.4G).   
 
Discussion 
 In this study we directly compared iPSCs to MSCs in terms of immunogenicity and 
immunomodulatory capability using mixed leukocyte reactions.  Our comparisons revealed that 
iPSCs generated through both lentiviral and piggyBac reprogramming methods have similar 
immunogenic properties as MSCs and may possess more potent immunomodulatory properties 
than MSCs in vitro.  Co-culture of MHC-mismatched leukocytes with MHC-matched iPSCs 
resulted in significantly less responder T cell proliferation than observed for MHC-mismatched 
leukocytes alone at more responder leukocyte concentrations tested than was observed for co-
culture of MHC-mismatched leukocytes with MHC-matched MSCs.  In addition, MHC-
mismatched iPSCs were able to significantly reduce responder T cell proliferation at the 
responder leukocyte concentration of 8x10^
5
 cells when co-cultured with MHC-mismatched 
leukocytes while MHC-mismatched MSCs were not. 
 None of the cells (MEFs, iPSCs, or MSCs) tested in this study were irradiated for use in 
MLRs due to the fact that iPSCs died following even very low doses (100-200 rads) of gamma 
irradiation.  This finding suggests that iPSCs undergo p53-independent apoptosis in response to 
DNA damage as described for ESCs [66-68] rather than p53-mediated cell cycle arrest as is well 
described for somatic cells [69]. For this reason, preliminary experiments were performed to 
determine the proper seeding density of all cell types such that they were approximately 80% 
confluent on the 5
th
 (final) day of MLR culture.  This method is different than most previously 
described for MSC immunology studies examining MSC effects in MLRs in which MSCs are 
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irradiated and then plated at different ratios to responder leukocytes [25, 41].  It is possible that 
because the cells in our experiments were growing that we could have either not reached or 
surpassed the optimal cell:leukocyte ratio for immunomodulation in some instances.  The fact 
that both MHC-matched iPSCs and MSCs were able to significantly downregulate  responder T 
cell proliferation to as much as 25-30% of that of the MHC-mismatched MLR, however, 
suggests that we covered a broad enough range of responder leukocyte cell concentrations to 
confidently determine if the cells were causing immunomodulation.  
 Due to the nature of our MLRs, it must be considered that T cell proliferation may have 
been falsely diminished due to T cell competition with the growing cells for nutrients in the 
media.  At no point during the experiments, however, did the media appear exhausted in color.  
More importantly, co-culture with control MEFs, which were rapidly growing and just as 
confluent as the other cell types by the end of the experiments, did not result in reduced T cell 
proliferation, arguing against nutrient competition or depletion as a reason for the reduced 
responder T cell proliferation observed in MLR co-cultures with iPSC and ESCs.  Another 
potential concern is that our leukocyte media included leukemia inhibitory factor (LIF), which 
has been shown to have a role in MSC-mediated immunosuppression [23].  LIF is commonly 
used in iPSC media to maintain pluripotency and prevent differentiation [1, 2, 10].  It was used 
in these experiments for that reason and also to avoid the use of feeder cells with iPSCs culture, 
which would have further complicated experimental design and interpretation [70].  As the same 
leukocyte media with LIF was used for all MLR experiments, this should have prevented any 
biases between cell type comparisons and against MHC-matched and mismatched MLR controls.  
Again, our finding that control MEFs did not cause significant downregulation of responder T 
cell proliferation argues against this concern. 
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 The finding that iPSCs and MSCs that were MHC-matched with respect to the responder 
leukocytes resulted in a greater reduction in responder T cell proliferation compared to iPSCs 
and MSCs that were MHC-mismatched is an interesting one.  Engraftment studies evaluating the 
effect of MSCs have previously demonstrated similar findings, with only syngeneic (MHC-
matched) MSCs resulting in enhanced engraftment [16, 37].  Previous MLR studies evaluating 
the immunosuppressive effects of ESCs, however, have found no difference in using MHC-
matched or mismatched ESCs with the responder leukocytes [71].  The reasons for this 
discrepancy between iPSCs and MSCs is unclear, but could be due to specific 
immunosuppressive mechanisms employed by the cells or due to the differences in MHC antigen 
expression between the cell types with iPSC expressing very low or negligible levels of MHC 
class I and MSCs expressing high levels of MHC I.    Further studies must be performed to 
elucidate this finding, including examination of soluble factors potentially expressed by iPSCs 
and MSCs into the media during MLRs such IL-10, TGF-β, PGE-2, IDO, and LIF [12, 13, 15, 
23, 31, 72]. 
 A very important question raised by this study is whether or not iPSCs can retain their 
immunogenic and immunomodulatory properties upon differentiation.  Additional follow up 
studies will focus on differentiating these same iPSC cell lines into specific cell types and then 
re-evaluating their MHC class I and II expression in addition to their immunogenic and 
immunomodulatory properties in MLRs.  Soluble factor release into the media by these cells 
during MLRs will also be re-assessed and compared to levels pre-differentiation.  As it is 
unlikely that undifferentiated iPSCs will be used in human clinical applications due to concerns 
of teratoma formation, these follow-up studies will be critical for consideration of iPSC use in 
the place of MSCs for both regenerative medicine and transplant medicine [7, 11, 50].   
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Abstract 
 The horse is a valuable species to assess the effect of allogeneic mesenchymal stem cells 
(MSCs) in regenerative therapy treatments.  There are no studies to date that have examined 
donor response to major histocompatibility (MHC)-mismatched equine MSCs.  The purposes of 
this study were to immunophenotype bone marrow-derived MSCs from horses of known MHC 
haplotype and to compare the immunogenicity of MSCs with differing immunophenotypes, 
particularly in regards to MHC class II expression through modified one-way mixed leukocyte 
reactions (MLRs).  Our hypotheses were that early passage MSCs would be heterogeneous in 
MHC class II expression and that MHC-mismatched MHC class II negative MSCs would have 
low immunogenicity in vitro while those that were positive would be immunogenic.  MSCs 
(n=10 horses, 13 bone marrow aspirates) varied widely in MHC class II expression through cell 
passages.  MSCs from 11 of 13 aspirates were positive for MHC II expression at P2 and 6 of 
those 11 remained positive through P8. MSCs from only one horse were MHC class II negative 
from P2 through P8, and results were repeatable on a second aspirate.  MLR results revealed that 
MHC-mismatched MHC class II positive MSCs caused significantly increased responder T cell 
proliferation compared to MHC-mismatched MHC class II negative and MHC-matched MSCs, 
and equivalent to that of the positive control of MHC-mismatched peripheral blood leukocytes.  
These results suggest that MHC-mismatched MSCs should be immunophenotyped and 
confirmed as MHC class II negative prior to potential application in order to reduce the risk of 
allogeneic reactions. 
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Introduction 
 The immune status and immunosuppressive properties of adult bone marrow-derived 
mesenchymal stem cells (MSCs) have been investigated in multiple species over the past decade 
with conflicting results [1-4].  While MSCs are commonly thought of and referred to as 
immunoprivileged in the literature, multiple studies in both mice and humans have demonstrated 
that allogeneic adult bone marrow-derived MSCs are capable of eliciting immune responses both 
in vitro and in vivo [1, 5-9].   In these studies, the immunosuppressive effects of MSCs were 
unable to prevent an immunogenic response in vitro, or to prevent MSC rejection in vivo.  
Complicating our understanding of the immune status of MSCs is the fact that not all MSCs 
described in the literature have the same major histocompatibility complex (MHC) class II 
expression profile [5, 6, 10], and some studies did not include MSC immunophenotyping and/or 
proper experimental controls [1].    
 Mesenchymal stem cells are increasingly used in regenerative therapies for equine 
patients [11-15].  The use of allogeneic MSCs would be advantageous in cases where treatment 
is indicated at the time of diagnosis.  Bone marrow-derived MSCs isolated from young adult 
horses have been previously phenotyped during mid-late passage (P3-P7) as MHC class II 
negative [16-18], and equine allogeneic MSCs have been reported to be both immunoprivileged 
and immunosuppressive in vitro [18], as well as non-immunogenic in vivo [19].   No studies 
have examined the immunophenotype of equine MCSs isolated from horses of varying age or 
sequentially over early to late passages.  In addition, no studies to date have used MSCs and 
leukocytes isolated from horses of known MHC haplotype, which is essential for performing 
MHC-matched and MHC-mismatched studies.  As the horse is a valuable species for assessing 
the effect of MSC treatment on musculoskeletal disorders such as tendonitis, cartilage damage, 
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and osteoarthritis [13, 20-25], it is critical to understand the immune status of equine MSCs prior 
to evaluating the use of allogeneic MSCs for “off the shelf” therapy in such models.   
 The purposes of this study were to: (1) phenotype P2-P8 bone marrow-derived MSCs 
from horses of known MHC haplotype; and (2) compare the immunogenicity of MSCs with 
differing immunophenotypes, particularly in regards to MHC class II expression, through 
modified one-way mixed leukocyte reactions (MLRs).  This is the first equine study that 
evaluates the immune response elicited by MHC-matched and MHC-mismatched MSCs, 
including controls of MHC-matched and mismatched peripheral blood leukocytes (PBLs).  Our 
first hypothesis, based on previous human early passage MSC immunophenotyping [10], was 
that early passage equine MSCs would be heterogeneous in MHC class II expression.  Our 
second hypothesis was that MHC-mismatched MHC class II negative MSCs would have low 
immunogenicity in vitro while those that were positive would be immunogenic.   
 
Materials and Methods 
Horses: Thoroughbred horses of known MHC haplotype belonging to the Equine Genetics 
Center at the James A. Baker Institute for Animal Health were used in these studies in 
accordance with the guidelines of the Institutional Animal Care and Use Committee of Cornell 
University.  All horses were MHC homozygotes of equine leukocyte antigen (ELA) haplotypes 
ELA-A2, ELA-A3, or ELA-A9 as previously determined by ELA serotyping, direct MHC gene 
sequencing, and microsatellite typing [26-29].   
Peripheral blood leukocytes: Blood was collected via jugular venipuncture with extension sets 
(Baxter Healthcare, Deerfield, IL) and 16 gauge needles into 500mL evacuated containers 
(Baxter Healthcare, Deerfield, IL) containing 7,500 units of heparin (Sigma-Aldrich, St. Louis, 
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MO) each.  Plasma was allowed to separate for 20 minutes at room temperature and peripheral 
blood leukocytes (PBLs) were then isolated from the plasma via carbonyl iron (Sigma-Aldrich, 
St. Louis, MO) granulocyte depletion and Ficoll-Paque Plus (Amersham Biosciences, 
Piscataway,NJ) gradient centrifugation.  PBLs were resuspended in RPMI 1040 medium (Gibco, 
Grand Island, NY) containing 10% fetal bovine serum (FBS), 0.1 mM 2-Mercaptoethanol, 
penicillin (100 units/mL) and streptomycin (100μg/mL) and fresh cells used for all experiments. 
Bone marrow aspirate collection and isolation of MSCs: Bone marrow aspirate was collected 
aseptically from the sternum of 10 horses using 11-gauge Jamshidi bone marrow biopsy needles 
under standing sedation with local anesthesia.  For each harvest, a total of 120mL of aspirate was 
collected into 60mL syringes containing 25,000 units of heparin each.  Three horses underwent a 
second aspirate collection 2 months after the first for a total of 13 aspirates (6 ELA-A2, 6 ELA-
A3, 1 ELA-A9 haplotypes).  Bone marrow aspirates were purified via Ficoll-Paque Plus 
(Amersham Biosciences, Piscataway,NJ) gradient centrifugation as previously described [30] 
and plated onto 100mm tissue culture plates in low glucose (1g/dL) DMEM media (Gibco, 
Grand Island, NY) containing 10% FBS, 2 mM l-glutamine, penicillin (100units/mL), 
streptomycin (100μg/mL), and basic fibroblastic growth factor (bFGF, 1ng/mL).  MSCs were 
expanded over 1 passage such that cryopreserved passage 2 (P2) stocks were obtained for each 
aspirate.  P2 MSCs were later thawed and cultured through P8.  At each passage, MSC stocks 
were cryopreserved for immunophenotyping and mixed leukocyte reactions (MLRs).  
Throughout culturing, media were exchanged every 48 hours.  Cells were passaged 1:3 at 
approximately 80% subconfluency using Accumax® cell dissociation solution (Innovative Cell 
Technologies Inc, SanDiego, CA) and plated at a density of approximately 1x10
4 
cells/cm
2
.   
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Immunophenotyping of MSCs: MSCs were immunophenotyped at each passage (2 to 8) for 
expression levels of MHC class I, MHC class II, and a panel of positive (CD44, CD29, CD90) 
and negative (CD11a/CD18, CD45RB) markers using flow cytometry.  Antibodies for these 
markers were previously validated for the horse and described by our laboratory [30].  PBLs and 
dermal fibroblasts were used as controls.  MSCs from each horse were directly compared to their 
own PBLs for expression levels of MHC class II to ensure that any variability in MSC MHC 
class II expression was not due to individual horse variability in MHC class II antibody binding.  
Cells were pelleted in aliquots containing approximately 1x10
6
 cells on 96-well V-bottom plates 
and treated with a 20 min blocking step using 10% normal goat serum in phosphate-buffered 
saline (PBS). The cells were pelleted and resuspended in unconjugated primary monoclonal 
antibody and incubated for 45 min at 4°C. Cells were then washed, a secondary fluorescent-
conjugated goat anti-mouse IgG antibody (fluorescein isothiocyanate (FITC; read on FL1) or 
allophycocyanin (APC; read on FL4), BD Biosciences, San Jose, CA) was applied to the 
unconjugated antibodies, and the samples incubated for an additional 45 min at 4°C.  Cells were 
washed and then resuspended in PBS and analyzed on a FACSCalibur (Becton Dickinson 
Immunocytometry Systems, San Jose, CA) flow cytometer equipped with 488 μm argon and 635 
μm red diode lasers and BD Cell Quest™ analysis software (BD Biosciences, San Jose, CA). 
Cells exposed to mouse antiparvovirus antibody and FITC or APC-conjugated secondary 
antibodies were used as negative isotype controls.  Cells were gated as previously determined for 
cultured MSCs by our laboratory [30] and data were collected on 2x10
4
 cells for each sample. 
IFN-ɣ stimulation of MSCs: Recombinant equine IFN-ɣ (R&D Systems Inc., Minneapolis, MN) 
was used to stimulate MSCs in culture, following which expression levels of MHC class II were 
assessed via flow cytometry.  MSCs were plated on 100mm tissue culture plates at a density of 
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1x10
4
 cells/cm
2 
in MSC media as described above and allowed to adhere to plates.  At 24 hours 
in culture, media on control plates were exchanged with fresh MSC media, while media on 
treated plates were exchanged with fresh MSC media containing 100ng/mL of IFN- ɣ [16, 31, 
32].  At 72 hours, media on control and treated plates were again exchanged in the same manner.  
At 96 hours, cells were dissociated from the plates and analyzed for MHC class II expression 
using flow cytometry as described above for immunophenotyping.   
MHC class II antibody comparison: Most previously published studies examining MHC class II 
expression levels of equine MSCs have used a commercially available MHC class II antibody 
(clone CVS20, AbD Serotec, Raleigh, NC), we compared this antibody to the one used in this 
study for immunophenotyping (cz11, clone 130.8E8D9, Laboratory of Dr. D. Antczak, Cornell 
University, Ithaca, NY) .  Both antibodies were generated from mouse hybridomas and are of the 
IgG1 isotype.  PBLs, MSCs, and MSCs stimulated with IFN-ɣ were used to make comparisons 
in MHC class II expression levels using the 2 antibodies.  For both primary mouse anti-horse 
MHC class II antibodies, a secondary goat anti-mouse APC antibody (BD Biosciences, San Jose, 
CA) was used.  Cells exposed to mouse antiparvovirus antibody with the same secondary 
antibody were used as negative isotype controls. 
Modified one-way mixed leukocyte reactions: To assess the ability of MSCs to stimulate an 
immune response, modified one-way mixed leukocyte reactions (MLRs) were performed in 
duplicate on 24-well tissue culture plates using MHC-matched and mismatched responder PBLs 
and stimulator MSCs.  MHC-matched stimulator PBLs were used as negative MLR controls 
(baseline T cell proliferation) and MHC-mismatched stimulator PBLs were used as positive 
MLR controls. Responder PBLs were labeled with 5(6)-carboxyfluorescein diacetate N-
succinimidyl ester (0.25μg/mL of cell solution,CFSE, Sigma-Aldrich, St. Louis, MO) and 
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examined at 2 different concentrations (1.5x10
6
 and 2.5x10
6
 cells/well).  Proliferative ability of 
responder cells was verified via mitogen stimulation with concanavalin A (ConA (5 μg/ml, 
Sigma-Aldrich, St. Louis, MO)). Stimulator MSCs were plated at 5x10
4
 cells/well in MSC media 
24 hours prior to the addition of responder PBLs such that MSCs would be approximately 80% 
confluent by the end of the experiment. Stimulator PBLs were irradiated with 9 Gy from a Cs-
137 source to inhibit proliferation and plated at 1.2x10
6
 cells/well immediately prior to the 
addition of responder PBLs.  The resultant ratios of responder:stimulator PBLs was based on 
previously published equine MLR experiments [33] and determined to be optimal for these 
studies in preliminary experiments. Cultures were maintained for 5 days with modified RPMI 
1040 media (1mL/well) containing 10% FBS, 0.1 mM 2-mercaptoethanol, penicillin 
(100units/mL), streptomycin (100μg/mL), and basic fibroblastic growth factor (bFGF, 1ng/mL).  
Media were not exchanged over the 5 days.  Following culture, PBLs were aspirated from the 
wells and stained with a primary mouse anti-horse CD3 antibody (clone UC F6G-3.3; Laboratory 
of Dr. J. Scott, University of California Davis, Davis, CA) and a secondary goat anti-mouse APC 
antibody (BD Biosciences, San Jose, CA).  The antibody staining process for flow cytometry 
analysis was performed as described above for immunophenotyping.  
 Proliferation of gated CFSE-labeled CD3-positive responder T cells was evaluated via 
CFSE attenuation using flow cytometry.  Cells were first gated on FL4 so that only the CD3-
positive cells (T cells) were then examined on FL1 for CFSE attenuation. Non-stimulated 
responder T cells were used to set the boundary of non-proliferating cells such that all cells to the 
left (lower fluorescence intensity on FL1) of that boundary were determined to be proliferating. 
The number of cell counts in the proliferating T cell gate was measured as well as the CFSE 
Geometric Mean Fluorescence Intensity (GMFI) of all T cells to reflect the extent of 
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proliferation.  Data was collected on the entirety of each sample because cell numbers were 
being measured. 
 MLRs were performed in a total of 5 experiments using responder PBLs from 4 different 
horses (2 ELA-A2, 1 ELA-A3 and 1 ELA-A9 haplotypes) and stimulator PBLs from 3 different 
horses (1 ELA-A2 and 2 ELA-A3 haplotypes).  In each experiment, T cell proliferation in 
response to MHC-matched MSCs, MHC-mismatched MHC class II negative MSCs, and MHC-
mismatched MHC class II positive MSCs was assessed.  As stated above, T cell proliferation in 
response to MHC-matched PBLs (MHC-matched MLR) was used as a negative control and set 
as the baseline proliferation value, while T cell proliferation in response to MHC-mismatched 
PBLs (MHC-mismatched MLR) was used as a positive control.  Due to naturally occurring 
variation in PBL responses between horses and experiments, the relative T cell proliferation and 
relative GMFI in each experiment was reported as the fold change from that of the MHC-
matched MLR. 
Statistical Analyses: Immunophenotyping data were analyzed with Pearsons correlations.  MHC 
class II expression data obtained by the two different antibodies were analyzed with paired t-
tests.  MLR data were normalized by log transformation and analyzed with analysis of 
covariance (ANCOVA), with horse as a covariate, followed by the Tukey test for multiple 
comparisons. All analyses were performed using Statistix 9 software (Analytical Software, 
Tallahassee, FL) and significance was set at P < 0.05. 
 
Results 
MSC isolation and immunophenotyping: MSCs were isolated and expanded from 13 of 13 bone 
marrow aspirates.  The percentage of P2 MSCs positive for MHC class II expression varied 
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widely amongst horses despite fairly consistent results for PBL MHC class II expression 
indicating that the MSC variation observed was not due to differences in antibody binding (Fig. 
1).  P2 MSCs from 11 of the 13 aspirates were positive for MHC class II expression with broad 
and diffuse expression peaks as opposed to a well-defined narrow peak or 2 or more peaks 
suggestive of different but limited cell populations (Figure 4.1).  P2 MSCs from only one horse 
(horse 5, ELA-A3 haplotype) were negative for MHC class II expression.   P2 MSCs from all 13 
aspirates had a phenotype of MHC I
hi
, CD44
hi
, CD29
hi
, and CD45RB
lo
 (Table 4.1).  Consistent 
with previous studies between 17-21 days of culture, there was variable expression of CD90 and 
CD11a/CD18 surface molecules [30] with the majority of the P2 MSCs having a phenotype of 
CD90
hi
 and CD11a/CD18
lo 
(Table 4.1).   Variability was also observed in P2 MSC morphology 
in that some MHC class II positive MSCs had the classic long spindle shaped morphology 
equivalent to that of the MHC class II negative MSCs while other MHC class II positive MSCs 
were more triangular to polygonal in shape and smaller in size (Figure 4.2).  All MSCs isolated 
from older horses (≥ 10 years of age) displayed some degree of atypical morphology. 
 MSCs from 6 of the 11 aspirates positive for MHC class II expression at P2 remained 
positive through P8, while MSCs from the other 5 aspirates became negative over time in 
culture, generally by P4 or P5 (Table 4.2).  Later passage MHC class II positive MSCs either 
maintained a broad and diffuse expression peak or converted to a narrower peak indicating 
upregulation of MHC class II in some cases (Figure 4.3).  P2 MSCs negative for MHC class II 
expression (2 aspirates from horse 5, ELA-A3 haplotype) remained negative through P8.  MSCs 
from all 13 aspirates each maintained their morphology exhibited in P2, regardless of whether or 
not they converted from MHC class II positive to MHC class II negative.   Only in this single 
ELA-A3 haplotype horse with MHC class II negative MSCs from P2-P8 could a correlation be 
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made between MHC haplotype and MSC MHC class II expression.  Interestingly, of the MSCs 
isolated from the 4 older horses in this study ≥ 10 years of age (2 ELA-A3, 1 ELA-A2, and 1 
ELA-A9 haplotypes), all were strongly positive for MHC class II at P2 and only those of the 
ELA-A9 haplotype became negative later in the culture period at P7 and P8 (Table 4.2).    
 Over the culture period through P8, all MSCs maintained the phenotype of MHC I
hi
, 
CD44
hi
, CD29
hi
, and CD45RB
lo
 as well as the previously observed variability in expression of 
CD90 and CD11a/CD18 surface molecules.  The median percentage of cells positive for CD90 
was 89.75% (range 3.58 – 99.64%) and the median percentage of cells positive for CD11a/CD18 
was 1.53% (range 0.12 to 70.85%).  A weak but significant negative correlation was found 
between CD90 and MHC class II expression (r = -0.23; P = 0.03) and a moderate positive 
correlation was found between CD11a/CD18 and MHC class II expression (r = 0.40; P ˂ 0.01).   
IFN-ɣ stimulation of MSCs and MHC class II antibody comparison: Stimulation of MHC class 
II negative MSCs with IFN-ɣ resulted in markedly increased expression of MHC II (Figure 4.4) 
in both the percentage of cells positive for MHC class II and the fluorescence intensity of the 
cells.  No significant differences were found between MHC class II expression levels (percentage 
of cells positive) obtained by the two different antibodies for PBLs (n = 3; P = 0.83), MSCs (n = 
4; P = 0.41), or IFN-ɣ stimulated MSCs (n = 3; P = 0.20). Some variability was observed, 
however, in the fluorescence intensity of the MSCs stained with the different antibodies, with the 
commercially available antibody (Antibody 2, clone CVS20) generating a more diffuse intensity 
than the antibody used in this study (Antibody 1, cz11, clone 130.8E8D9) (Figure 4.4). 
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Figure 4.1.  Flow cytometric histogram analyses of MHC class II expression in peripheral blood 
leukocytes (PBLs) and passage 2 bone marrow-derived mesenchymal stem cells (P2 MSCs) for 
horses 1-10.  The open lines represent negative isotype control staining and the shaded curves 
represent MHC class II staining.  The percentage of positive cells is in the upper right-hand 
corner of each histogram.  Note the relatively minor variation in PBL MHC class II expression 
between horses as compared to the major variation in P2 MSC MHC class II expression. 
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Figure 4.2. Examples of bone marrow-derived mesenchymal stem cell (MSC) morphology 
observed for MHC class II negative cells (A and B) and MHC class II positive cells (C-F).  Note 
that some MHC class II negative cells (C and D) displayed the classic spindle shape morphology 
equivalent to that observed for MHC class II negative cells, while others displayed a less 
characteristic morphology (E and F).  Also note that the MSCs maintained their morphology 
over multiple passages whether or not they converted to MHC class II negative or not.  In the 
example shown here, MSCs from horse 9 had the same morphology at P2 (MHC class II 
positive; D) as they did at P5 (MHC class II negative; B).   
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Figure 4.3.  Flow cytometric histogram analyses of MHC class II expression in passage 2 (P2) 
and passage 8 (P8) bone marrow-derived mesenchymal stem cells (MSCs).  The open lines 
represent negative isotype control staining and the shaded curves represent MHC class II 
staining.  The percentage of positive cells is described in the upper right-hand corner of each 
histogram.  Note the variability in both the percentage of cells positive for MHC class II 
expression at P8 as well as the variability in fluorescence intensity for those MSCs that remained 
MHC class II positive at P8 (Horses 7 and 10 in this figure).  
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Figure 4.4.  Flow cytometric histogram analyses of MHC class II expression in control or 
untreated bone marrow-derived stem cells (MSCs) and in IFN-ɣ stimulated MSCs used to 
compare the antibody used in this study (Antibody 1) to the commercially available antibody 
(Antibody 2).  The open lines represent negative isotype control staining and the shaded curves 
represent MHC class II staining.  Note the consistency observed between antibodies for all cell 
types, with the exception of the fact that MSC class II positive MSCs generally displayed a more 
diffuse fluorescence intensity when stained with Antibody 2 compared to Antibody 1. 
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Modified one-way mixed leukocyte reactions: MHC-mismatched MHC class II positive MSCs 
caused a significant increase in responder T cell proliferation compared to MHC-mismatched 
MHC class II negative MSCs at the lower responder PBL concentration of 1.5x10^6 cells 
(Figure 4.5A; P ˂ 0.01) and compared to both MHC-mismatched MHC class II negative and 
MHC-matched MSCs at the higher responder PBL concentration of 2.5x10^6 cells (Figure 4.5B; 
P ˂ 0.01).  At both responder T cell concentrations, proliferation caused by MHC-mismatched 
MHC class II positive MSCs was statistically equivalent to that caused by the positive control of 
MHC-mismatched PBLs.   MHC-mismatched MHC class II negative MSCs used in experiments 
were Horse 5 (ELA-A3) P2 MSCs and Horse 9 (ELA-A2) P5 MSCs.  MHC-mismatched MHC 
class II positive MSCs used in experiments were Horse 7 (ELA-A3) P2 MSCs and Horse 5 
(ELA-A3) P2 IFN-ɣ stimulated MSCs.  Responder T cell proliferation results for individual 
experiments are shown in Figure 4.6. 
 Stimulation of responder PBLs with MHC-mismatched MHC class II positive MSCs 
resulted in lower responder T cell GMFI, indicative of an increased number of cell divisions, 
compared to MHC-mismatched MHC class II negative MSCs (Figure 4.5C and Figure 4.5D).  
This result was significant at the higher responder PBL concentration of 2.5x10^6 cells (Figure 
4.5D; P = 0.02).  At both responder PBL concentrations, stimulation of responder PBLs with 
either MHC-mismatched MHC class II negative MSCs or MHC-mismatched MHC class II 
positive MSCs resulted in responder T cell GMFI statistically equivalent to that of both MHC-
matched MSCs and MHC-mismatched PBLs. 
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Figure 4.5.   Modified one-way mixed leukocyte reaction (MLR) results at the lower responder 
cell concentration of 1.5x10
6
 leukocytes (A and C) and at the higher responder cell concentration 
of 2.5x10
6
 leukocytes (B and D) as measured by relative responder T cell proliferation (A and B) 
and CFSE geometric mean fluorescence intensity (GMFI; C and D).  Bars represent mean ± S.D. 
of n = 5. Superscript letters indicate significant differences between groups by ANCOVA, with 
horse as a covariate, followed by the Tukey test for multiple comparisons, P < 0.05.  MHC-M = 
MHC-matched; MHC-MM = MHC-mismatched.  MHC-mismatched MHC class II negative 
MSCs caused significantly less responder T cell proliferation compared to both the positive 
control of MHC-mismatched PBLs (MHC-MM MLR) and MHC-mismatched MHC class II 
positive MSCs at both responder leukocyte concentrations (A; P ˂ 0.01 and B; P ˂ 0.01).  MHC-
mismatched MHC class II negative MSCs resulted in a significantly greater CFSE GMFI, 
indicative of fewer responder T cell divisions, compared to MHC-mismatched MHC class II 
positive cells at the higher responder leukocyte concentration (D; P = 0.02). 
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Figure 4.6.  Responder T cell proliferation results for individual experiments (A-E) used to 
generate Figure 4.5A and Figure 4.5B.  MHC-M = MHC-matched; MHC-MM = MHC-
mismatched.  Note that for every experiment the responder T cell proliferation in response to 
MHC-mismatched MHC class II positive MSCs was greater than that observed for the 
negative/baseline control of MHC-matched PBLs (MHC-M MLR), MHC-mismatched MHC 
class II negative MSCs, MHC-matched MSCs.   
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Discussion 
 This study reports the heterogeneous immunophenotypes of bone marrow-derived MSCs 
isolated from horses of varying age and MHC haplotype.  We hypothesized that MSCs would 
variably express MHC class II during early passages as has been previously shown for human 
and mouse MSCs [5-6,10], and that this expression would decrease over time in culture such that 
MSCs would be negative for MHC class II expression at later passages.  While this turned out to 
be the case for MSCs isolated from certain horses, others remained strongly positive for MHC 
class II expression through P8.  This variability observed in MHC class II expression was not 
due to differences in antibody binding between horses as determined by comparison of PBL 
MHC class II expression and also was not due to differences in antibody binding between the 
antibody primarily used in this study (Antibody 1) and the antibody used in previous studies 
(Antibody 2) as demonstrated in Figure 4.2.  Interestingly, even MSCs isolated from different 
bone marrow aspirate harvests from the same horse were found to differ in MHC class II 
expression.  These results suggest that a combination of factors including genetics, bone marrow 
aspirate quality, immunologic background at a given point in time, and culture conditions are 
responsible for the extreme heterogeneity of MHC class II expression observed.   
 Similar to the majority of the equine MSCs in this study, human MSCs found to be MHC 
class II positive displayed a diffuse or broad MHC class II expression peak on flow cytometry 
histogram analysis suggestive that the individual MSCs themselves varied in terms of the 
number of MHC class II molecules expressed on their cell surface [6].  Both mouse and human 
MSCs in these studies otherwise had the expected profile of positive and negative markers for 
“stemness” and were capable of tri- lineage differentiation as typical for MSCs.  While tri-
lineage differentiation assays were not performed in this study, equine MSCs cultured in our 
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laboratory using the same methods have previously been shown to be capable of in vitro 
adipogenic, osteogenic, and chondrogenic differentiation [30].  Although it is possible, or 
perhaps even likely, that the cultured cells collectively referred to as MSCs are not all stem cells, 
at no time during flow cytometric analysis of MSCs from any horses in this study did there 
appear to be two or more distinct cell types or cells with distinct marker profiles.  All MSCs 
remained with the previously determined MSC gate and consistently expressed the CD44
hi
, 
CD29
hi
, and CD45RB
lo
 phenotype [30].  This suggests that MSCs themselves are capable of 
extreme variation in MHC class II expression. 
 The variation observed in expression of the cell surface markers CD90 and CD11a/CD18 
(LFA-1) is difficult to interpret as it has previously been shown that equine bone marrow-derived 
MSCs express variable levels of these markers, and that their expression changes over time in 
culture such that cells are CD90
lo 
and CD11a/CD18
hi 
early on but become CD90
hi
 and 
CD11a/CD18
hi 
over time. [30].  Such variability may be expected when using examining cells 
from different donors.  A weak negative correlation was found between CD90 and MHC class II 
expression when analyzing the phenotype data as a whole, but this correlation was not consistent 
for the same MSCs over multiple passages.  There were numerous examples of MSCs that 
remained strongly positive for MHC class II over several passages but whose expression of 
CD90 increased over those same passages.  Similarly, while a moderate positive correlation was 
found between CD11a/CD18 and MHC class II expression, there were numerous examples of 
MSCs that remained MHC class II positive over several passages but whose expression of 
CD11a/CD18 decreased.  These findings suggest that such correlations may be more of a 
temporal finding than a defining finding as the greatest number of MSCs were MHC class II 
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positive during early passages, when we would expect CD90 expression to be low and 
CD11a/CD18 expression to be high [30]. 
 The finding that the majority of passage 2-4 MSCs in this study were positive for MHC 
class II expression has not been previously described.  Equine studies examining MHC class II 
expression and immunogenic properties of MSCs to date have largely focused on later passage 
cells [17, 18, 34], even though most MSCs used in experimental models and in clinical 
applications are early passage in order to maintain proliferative ability [20, 21, 35, 36].  This 
knowledge is critical for potential allogeneic applications, as MHC-mismatched MHC class II 
positive MSCs incited significant proliferation of T cells from responder horses of all ELA 
haplotypes (A2, A3, and A9) examined in this study.  This underscores the caution that must be 
taken when using allogeneic MSCs.  Thoroughbreds were used in the present study, but most 
breeds of horses can have multiple ELA haplotypes [29, 37].  It is therefore not safe to assume 
that donor MSCs from any breed of horse can be used in a recipient horse of the same breed 
without the potential for an immune reaction.   
 The results of this study suggest that MSCs should be immunophenotyped and confirmed 
as MHC class II negative prior to allogeneic application.   As demonstrated, examination of 
MSCs for classic morphologic characteristics cannot be used alone to assess the potential for 
MHC class II expression. While all MSCs in this study that displayed less desirable morphologic 
characteristics were MHC class II positive, some MSCs displaying the classic morphology were 
also found to be MHC class II positive.  Both the quantity and quality of MSCs decreases with 
advanced donor age [38-40], so younger horses are sought as donors.  However, in the present 
study, even MSCs isolated from the younger horses that had the classic morphology were MHC 
class II positive.  Additionally, it must be considered that even MHC class II negative MSCs 
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could potentially upregulate their MHC class II expression if implanted into an area of active 
inflammation as was demonstrated upon in vitro stimulation with IFN-ɣ.   
 In summary, we have shown that equine MSCs are heterogeneous in MHC class II 
expression and that MHC-mismatched MHC class II positive MSCs are capable of inciting an 
immune reaction in vitro.  It is essential that all potential donor MSCs be immunophenotyped 
and screened for MHC class II expression.  Further studies are warranted to determine the in 
vivo response to MHC-mismatched MSCs that are either MHC class II negative or MHC class II 
positive as well as the effect of multiple injections of these cells on a recipient’s immune 
response.  Further research is also required to determine the effect of MHC class II expression on 
equine MSC immunosuppressive properties. 
  
 119 
 
REFERENCES 
  
1. Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune 
responses elicited by allogeneic mesenchymal stem cells: What have we learned so far? Immunol 
Cell Biol. 2013; 91: 40-51.  
2. Stagg J, Galipeau J. Immune plasticity of bone marrow-derived mesenchymal stromal cells. 
Handb Exp Pharmacol. 2007; (180): 45-66.  
3. Stagg J. Immune regulation by mesenchymal stem cells: Two sides to the coin. Tissue 
Antigens. 2007; 69: 1-9.  
4. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell 
therapies Hum Gene Ther. 2010; 21: 1641-1655.  
5. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are 
immune rejected by MHC class I- and class II-mismatched recipient mice. Blood. 2005; 106: 
4057-4065.  
6. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of 
mesenchymal stem cells: Functional discrimination between cellular responses to alloantigens 
and recall antigens. J Immunol. 2003; 171: 3426-3434.  
7. Zangi L, Margalit R, Reich-Zeliger S, Bachar-Lustig E, Beilhack A, Negrin R, Reisner Y. 
Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal 
cells. Stem Cells. 2009; 27: 2865-2874.  
8. Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW. Murine bone marrow stromal 
progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol Blood Marrow 
Transplant. 2007; 13: 412-422.  
9. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-
derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor 
graft rejection in a nonmyeloablative setting. Blood. 2006; 108: 2114-2120.  
10. Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM, Markham AF, 
Jack A, Emery P, McGonagle D. Isolation and characterization of bone marrow multipotential 
mesenchymal progenitor cells. Arthritis Rheum. 2002; 46: 3349-3360.  
11. Fortier LA. Making progress in the what, when and where of regenerative medicine for our 
equine patients Equine Vet J. 2012; 44: 511-512.  
 120 
 
12. Fortier LA, Travis AJ. Stem cells in veterinary medicine. Stem Cell Res Ther. 2011 Feb 23; 
2: 9.  
13. Frisbie DD, Smith RK. Clinical update on the use of mesenchymal stem cells in equine 
orthopaedics. Equine Vet J. 2010; 42: 86-89.  
14. Frisbie DD, Stewart MC. Cell-based therapies for equine joint disease. Vet Clin North Am 
Equine Pract. 2011; 27: 335-349.  
15. Schnabel LV, Fortier LA, McIlwraith CW, Nobert KM. Therapeutic use of stem cells in 
horses: Which type, how, and when? Vet J. 2013; In Review.  
16. Guest DJ, Ousey JC, Smith MRW. Defining the expression of marker genes in equine 
mesenchymal stromal cells. Stem Cell and Cloning: Advances and Applications. 2008; 1: 1-9.  
17. De Schauwer C, Meyer E, Van de Walle GR, Van Soom A. Markers of stemness in equine 
mesenchymal stem cells: A plea for uniformity. Theriogenology. 2011; 75: 1431-1443.  
18. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative 
analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells(). 
Cell Med. 2012; 4: 1-11.  
19. Guest DJ, Smith MR, Allen WR. Monitoring the fate of autologous and allogeneic 
mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: 
Preliminary study. Equine Vet J. 2008; 40: 178-181.  
20. Schnabel LV, Lynch ME, van der Meulen MC, Yeager AE, Kornatowski MA, Nixon AJ. 
Mesenchymal stem cells and insulin-like growth factor-I gene-enhanced mesenchymal stem cells 
improve structural aspects of healing in equine flexor digitorum superficialis tendons. J Orthop 
Res. 2009; 27: 1392-1398.  
21. Godwin EE, Young NJ, Dudhia J, Beamish IC, Smith RK. Implantation of bone marrow-
derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain 
injury of the superficial digital flexor tendon. Equine Vet J. 2012; 44: 25-32.  
22. Wilke MM, Nydam DV, Nixon AJ. Enhanced early chondrogenesis in articular defects 
following arthroscopic mesenchymal stem cell implantation in an equine model. J Orthop Res. 
2007; 25: 913-925.  
23. Ferris DJ, Frisbie DD, Kisiday JD, McIlwraith CW, Hague BA, Major MD, Schneider RK, 
Zubrod CJ, Kawcak CE, Goodrich LR. Vet Surg. 2013; In Press.  
24. Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW. Evaluation of adipose-
derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment 
of osteoarthritis. J Orthop Res. 2009; 27: 1675-1680.  
 121 
 
25. McIlwraith CW, Frisbie DD, Rodkey WG, Kisiday JD, Werpy NM, Kawcak CE, Steadman 
JR. Evaluation of intra-articular mesenchymal stem cells to augment healing of microfractured 
chondral defects. Arthroscopy. 2011; 27: 1552-1561.  
26. Lazary S, Antczak DF, Bailey E, Bell TK, Bernoco D, Byrns G, McClure JJ. Joint report of 
the fifth international workshop on lymphocyte alloantigens of the horse, baton rouge, louisiana, 
31 october-1 november 1987. Anim Genet. 1988; 19: 447-456.  
27. Tallmadge RL, Campbell JA, Miller DC, Antczak DF. Analysis of MHC class I genes across 
horse MHC haplotypes. Immunogenetics. 2010; 62: 159-172.  
28. Tallmadge RL, Lear TL, Antczak DF. Genomic characterization of MHC class I genes of the 
horse. Immunogenetics. 2005; 57: 763-774.  
29. Tseng CT, Miller D, Cassano J, Bailey E, Antczak DF. Identification of equine major 
histocompatibility complex haplotypes using polymorphic microsatellites. Anim Genet. 2010; 41 
Suppl 2: 150-153.  
30. Radcliffe CH, Flaminio MJ, Fortier LA. Temporal analysis of equine bone marrow aspirate 
during establishment of putative mesenchymal progenitor cell populations. Stem Cells Dev. 
2010; 19: 269-282.  
31. Chan WK, Lau AS, Li JC, Law HK, Lau YL, Chan GC. MHC expression kinetics and 
immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Exp 
Hematol. 2008; 36: 1545-1555.  
32. Romieu-Mourez R, Francois M, Boivin MN, Stagg J, Galipeau J. Regulation of MHC class II 
expression and antigen processing in murine and human mesenchymal stromal cells by IFN-
gamma, TGF-beta, and cell density. J Immunol. 2007; 179: 1549-1558.  
33. Flaminio MJ, Antczak DF. Inhibition of lymphocyte proliferation and activation: A 
mechanism used by equine invasive trophoblast to escape the maternal immune response. 
Placenta. 2005; 26: 148-159.  
34. Guest DJ, Allen WR. Expression of cell-surface antigens and embryonic stem cell 
pluripotency genes in equine blastocysts. Stem Cells Dev. 2007; 16: 789-796.  
35. Crovace A, Lacitignola L, De Siena R, Rossi G, Francioso E. Cell therapy for tendon repair 
in horses: An experimental study. Vet Res Commun. 2007; 31 Suppl 1: 281-283.  
36. Crovace A, Lacitignola L, Rossi G, Francioso E. Histological and immunohistochemical 
evaluation of autologous cultured bone marrow mesenchymal stem cells and bone marrow 
mononucleated cells in collagenase-induced tendinitis of equine superficial digital flexor tendon. 
Vet Med Int. 2010; 2010: 250978.  
 122 
 
37. Antczak DF, Bailey E, Barger B, Guerin G, Lazary S, McClure J, Mottironi VD, Symons R, 
Templeton J, Varewyck H. Joint report of the third international workshop on lymphocyte 
alloantigens of the horse, kennett square, pennsylvania, 25-27 april 1984. Anim Genet. 1986; 17: 
363-373.  
38. Delling U, Lindner K, Ribitsch I, Julke H, Brehm W. Comparison of bone marrow aspiration 
at the sternum and the tuber coxae in middle-aged horses. Can J Vet Res. 2012; 76: 52-56.  
39. Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere 
length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem 
Cells. 2004; 22: 675-682.  
40. Majors AK, Boehm CA, Nitto H, Midura RJ, Muschler GF. Characterization of human bone 
marrow stromal cells with respect to osteoblastic differentiation. J Orthop Res. 1997; 15: 546-
557.  
 
 
  
 123 
 
CHAPTER 5 
GENERAL DISCUSSION 
 
Application of Findings to Future Studies 
 The results of the studies presented in this dissertation have led to the formulation of 
many important biologic questions and to the design of future studies as discussed below.  
Importantly, before we can proceed to a comparison between equine MSCs and iPSCs for future 
in vivo studies to examine both the immunogenic, immunomodulatory, and regenerative 
properties of the cells, some unanswered questions concerning equine MSCs remain. 
 
Can we control culture conditions to decrease MHC class II expression by equine MSCs? 
 There are a large number of mediators known to affect MHC class II expression.  These 
mediators can be cell type dependent as well as species specific [1-3].  Mediators of particular 
interest to the regulation of MHC class II expression by equine MSCs during the culture period 
are bFGF (FGF-2) and TGF-β1.  In human MSC MHC class II expression studies, it has been 
demonstrated that bFGF in the culture media starting at P0 can cause markedly increased 
expression of MHC class II by MSCs [3, 4].  Interestingly, the same effect is not observed for 
mouse MSCs, which have previously been shown to have a different MHC class II regulation 
pathway than humans [5]. The upregulation of human MSC MHC class II expression by bFGF 
was consistent in all MSCs evaluated in a study by Bocelli-Tyndall et al. and was dose 
(0.1ng/mL to 10ng/mL) and donor dependent only in the degree of upregulation [3].  As we 
routinely use bFGF (1ng/mL) in our equine MSC media throughout the culture period, it would 
be very interesting to repeat bone marrow aspirates on a few of our MHC haplotyped horses 
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whose MSCs were previously MHC class II positive and to then isolate and culture expand their 
MSCs both with and without bFGF in the media to compare MHC class II expression.   
 It has also been demonstrated that TGF-β1 is able to reduce IFN-ɣ-induced MHC class II 
expression both in mice and human [5].  As we have already observed that IFN-ɣ stimulation of 
equine MSCs results in marked upregualtion of MHC class II expression, it would be logical as a 
next step to then determine if this upregulation can be reduced by the addition of TGF-β1 to the 
culture media.  The TGF-β1 used could be the recombinant protein or of even greater clinical 
interest would be to use platelet rich plasma (PRP) as a source of TGF-β1 [6].  As discussed in 
the “Current Status of Clinical Stem Cell Use in the Horse” section of chapter 1, it is common in 
equine practice to implant MSCs with PRP [7].  Could this be of potential benefit to 
downregulate MHC class II expression when implanting the MSCs clinically in area of active 
inflammation?  This is certainly an intriguing question that could be investigated preliminarily in 
vitro by culturing MSCs with IFN-ɣ alone, IFN-ɣ in addition to recombinant TGF-β1, and IFN-ɣ 
in addition to PRP to compare MHC class II expression. 
 In addition to soluble mediators, cell density has also been observed to affect MHC class 
II upregulation following IFN-ɣ stimulation [5].  Opposite effects were observed for human and 
mouse MSCs, with low-density human MSCs being more permissive of IFN-ɣ-induced MHC 
class II upregulation and high-density mouse MSCs being more permissive [5].  Equine MSCs in 
our study presented in chapter 4 were all passaged at approximately the same rate and density.  It 
would be interesting, therefore, to plate the MSCs at different densities and observe if there is 
any effect on MHC class II expression both with and without IFN-ɣ stimulation.  If certain cell 
culture conditions were able to prevent MHC class II expression by MSCs, this would alleviate a 
lot of our concern over a potential immunogenic response to allogeneic MSCs in vivo.  
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Does equine MSC MHC class II expressions affect their immunomodulatory properties in 
vitro? 
 Further in vitro studies are necessary to determine if equine MSC MHC class II 
expression affects their immunomodulatory properties.  While a preliminary study by Carrade et 
al. has demonstrated that equine bone marrow-derived MSCs are capable of immunomodulation 
in vitro, the MSCs used in that study were late passage MHC class II negative cells and the 
leukocytes used for the MLRs were not from haplotyped horses [8].  Therefore, in future studies 
we would use MSCs and PBLs isolated from our MHC haplotyped horses and test their 
immunomodulatory capability as described for mice in our study presented in chapter 3. 
 
What is the in vivo response to equine MSCs that are either MHC class II positive or negative 
prior to implantation? 
 While in vitro studies are necessary to understand basic biologic properties of MSCs and 
to gain preliminary data, of ultimate importance is the question of whether or not equine MSCs 
that are either MHC class II positive or negative prior to implantation can incite an immune 
response in vivo.  In order to assess this, a subdermal transplant model developed in Dr. 
Antczak’s laboratory will be used [9]. MSCs will be transplanted into the neck region of a MHC-
mismatched horse and serial blood and injection-site biopsy samples will be collected from the 
recipient horse once weekly for 4 weeks.  Lymphocyte microcytotoxicity assays will be used to 
measure the antibody response to the transplanted cells.  Peripheral blood leukocytes (PBLs) 
from the MSC-donor horse will be isolated and tested against antisera from the recipient horse.  
The cytotoxic antibody titer will be determined by the highest dilution of each serum (N) that 
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results in the death of at least 80% of the donor cells [9].  Cytotoxic antibody titer results will be 
reported as (1:N), where a higher N is indicative of a stronger cytotoxic antibody response and 
will be compared between MHC class II positive and negative MSCs.   
 Injection-site biopsy sections will be cryopreserved, sectioned and stained with 
monoclonal antibodies to equine leukocyte and MHC antigens. Morphometric analysis will be 
performed on 4 random fields of view as previously described by the Atczak laboratory to 
quantify mean T cell (CD3) and macrophage (CZ2.2) numbers between recipient horses for the 
different cell types [9]. Sections from MSC recipients will also be stained with monoclonal 
antibodies to equine MSCs (CD44 and CD29) for identification of MSCs.   
 Importantly, all of these in vitro and in vivo studies can also be used to compare the 
immunogenic and immunomodulatory properties of equine MSCs to equine iPSCs once we have 
generated iPSCs from our MHC haplotyped horses.  We have become proficient in the in vitro 
studies as described in this dissertation for both mice and horses, and our collaborator, Dr. 
Douglas Antczak, has extensive experience with the in vivo studies described above.  In 
addition, these in vivo studies are already partially funded by my National Institutes of Health 
Mentored Clinical Scientist Research Career Development Award (K08).   
 
Can implantation of MSCs with PRP reduce an immune response in vivo? 
 If we were to discover in our in vitro studies that PRP could downregulate MHC class II 
expression and if we were to find that allogeneic MSCs incited an immune response in vivo, we 
would then test whether or not implanting the MSCs with PRP in vivo results in abolishment of 
an immune reaction.  This information would be critical to future clinical application of MSCs 
and is quite relevant as that is how MSCs are being currently being implanted into tendon and 
 127 
 
other musculoskeletal lesions by many practitioners [7]  PRP is also routinely used in human 
sports medicine and could be applied in the same manner for human patients treated with MSCs 
[10-13]. 
 
If necessary, is it possible to prevent MHC class II expression by targeting CIITA, the master 
regulator of MHC class II gene expression? 
 Another intriguing idea for MHC class II modulation is to target class II transactivator 
(CIITA), the master regulator of MHC class II gene expression, either through transcriptional or 
post-translational modification [1, 2].  Naturally occurring epigenetic regulation of CIITA 
through promoter hypermethylation and histone deacetylation has been implicated as a cause of 
placental immune tolerance [1], and it has been demonstrated that treatment of trophoblasts with 
methylation and histone deacetylation inhibitors in addition to IFN-ɣ results in removal of CIITA 
transcriptional repression [1].  It is also known that CIITA is post-translationally modified by 
acetylation, phosphorylation and ubiquitylation [1]. The broad effects of treating MSCs with 
synthetic methylation, histone, or post-translational modifiers are unknown and likely complex 
but could potentially be of great value for manipulating the immune status of the cells. 
 
Clinical Relevance 
 As discussed throughout this dissertation, the field of regenerative medicine is in need of 
banked and screened stem cells that would essentially be “off the shelf” and ready for use upon a 
patient’s diagnosis.  It has previously been demonstrated that genetic background can affect 
MSC proliferation and differentiation rates [14].  In this dissertation research, we have also 
demonstrated that genetic background affects the ability to generate iPSCs.  It therefore may not 
 128 
 
be feasible to use autologous MSCs or iPSCs from all patients.  Even more importantly, the time 
it takes to isolate MSCs or to generate iPSCs and screen them for efficacy and safety is not 
practical in a clinical setting.  In order to advance the field by being able to treat our patients at 
an appropriate time, we need to have previously cultured and screened allogeneic cells available 
to us.   
 In the studies described in chapter 3, we have demonstrated that undifferentiated iPSCs 
have similar immunogenic and even more potent immunomodulatory properties than MSCs in 
vitro.  This is an important first step towards determining if these cells could be used in an 
allogeneic fashion.  As discussed, however, it is imperative to determine if iPSCs retain these 
properties upon differentiation for potential future use in regenerative or transplantation 
medicine. 
 In the studies described in chapter 4, we have reported for the first time the extreme 
heterogeneity that exists in MHC class II expression by equine MSCs and that MHC class II 
positive equine MSCs are capable of inciting an immune response in vitro.  This knowledge is 
critical for the treatment of our equine patients as well as for future studies using the horse as an 
animal model for human diseases.  Our next experiments to determine if we can modulate this 
MHC class II expression in culture will be of great interest prior to our in vivo studies to 
examine the immune response to allogeneic MSCs. 
 Through completion of these dissertation studies we have obtained the skills and 
knowledge needed to move forward and complete further studies which will aid in the 
understanding of the safety and efficacy of allogeneic stem cell therapy.  We are very fortunate 
to have the expertise of our collaborators and the generous use of the MHC haplotyped horses 
belonging to our collaborator, Dr. Douglas Antczak.   With such aid, we are making significant 
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progress toward our long-term goal of comparing not only the in vivo immunogenic and 
immunomodulatory properties of allogeneic equine MSCs and iPSCs, but also their regenerative 
potential in an equine tendonitis model which will benefit both equine and human patients.  
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